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Excess adipose tissue is a risk factor for developing colorectal cancer. 
However, the present studies demonstrate that lack of adipose-derived factor(s), 
such as adiponectin, due to the substantial loss of body fat on high dairy calcium 
diet could increase susceptibility to intestinal tumorigenesis. These studies 
suggest that a minimum amount or threshold level of adipose tissue may be 
required to significantly attenuate tumorigenesis.  
In ApcMin/+ mice, consumption of high dairy calcium diet exhibited markedly 
reduced adipose tissue and increased tumor number. Our results showed that the 
high calcium diet reduced fat pad mass by 65%-82% in ApcMin/+ (p<0.03) in 
comparison with low calcium diet. ApcMin/+ mice on the high calcium diet 
exhibited an increase in tumor number (76 vs. 29, p=0.009). Moreover, β-catenin 
gene and cyclin D1 gene expression were significantly induced in intestinal tumor 
tissue of ApcMin/+ mice on high calcium diet. These effects were not directly 
resulted from high dietary calcium feeding, but rather associated with loss of body 
fat mass. Tumor load was not affected by the calcium diet on obese 
Ay/ApcMin/+mice despite the fact that high dairy calcium diet produced a 
substantial loss of body fat, as there was still substantial residual adipose tissue 
remaining. Our results indicate that protective effects of calcium against 
colorectal cancer may be least apparent among lean individuals, suggesting that 
future studies of calcium and colorectal cancer should consider stratification of 
subjects according to adiposity. 
 v
    In an in vitro environment to determine the adipose-derived factor(s) 
responsible, we utilized a co-culture system to observe the influence of human 
adipocytes on the growth of Caco-2, a human colon cancer cell line. We found 
that human adipocytes substantially suppressed proliferation of Caco-2 by 62.8%. 
In addition, we reported that human adipocyte conditioned medium inhibited 
growth of Caco-2 cells by 28.0%-65.6% compare to DMEM. These findings 
suggest the protective effect of adipocytes on colonic tumorigenesis. To further 
investigate if adiponecin, a protein hormone secreted from mature adipocytes, is 
responsible for this inhibitory effect, anti-human adiponectin-neutralizing 
antibody was added into the human adipocyte conditioned medium (HACM) and 
to the co-culture system. The antibody blocked the growth-inhibiting effects in 
both human adipocytes (HA) and HACM. Consistent with this, siRNA-mediated 
decrease in adiponectin protein in human adipocytes prevented the inhibitory 
effect of human adipocytes on Caco-2 proliferation. These data demonstrated that 
human adipocytes inhibit Caco-2 proliferation and that adiponectin is responsible 
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Colorectal cancer is the 3rd most common cancer worldwide. The American 
Cancer Society estimates that the new cases of colon cancer will reach 112,340 
and the new cases of rectal cancer will be 41,420 in 2007 in the United States (1). 
Diet appears to be the most important exogenous factor identified in the etiology 
of colon cancer. It has been estimated that 70% of colorectal cancer could be 
prevented by nutritional intervention (2).  
    The association between calcium intake and the risk of colorectal cancer was 
first investigated by Garland in 1985 (3). After a 19-year prospective study of 
about 2000 people in Chicago, they found a strong inverse correlation between 
colorectal cancer risk and dietary vitamin D and calcium intake. After that, 
several observational studies, and interventional studies were conducted. 
Mounting evidence demonstrates that dietary calcium is inversely associated with 
the risk of colorectal cancer (4-9). Both in vitro and in vivo studies suggested that 
high calcium intake may reduce cytotoxicity of fecal water (10, 11) or inhibit 
epithelial cell proliferation (12, 13). However, our preliminary observations 
suggested that high calcium intake paradoxically promoted intestinal tumor 
growth in ApcMin/+ mice, and this effect was accompanied by a profound loss of 
adipose tissue. Since we have previously demonstrated that increasing dietary 
calcium effectively reduces adiposity (14, 15), we hypothesized that this 
excessive loss of adipose tissue resulted in increased tumor susceptibility in 
ApcMin/+ mice on the high calcium diet. 
 3
Adipose tissue is an active endocrine and metabolic organ that can have effects 
on the energy balance and lipid metabolism of other tissues. It also regulates their 
physiology through the release of hormones such as leptin, adiponectin, resistin 
and tumor necrosis factor-α (TNF-α). The relationship between excess body 
weight and the incidence of colon cancer has been well established in 
epidemiological studies (16-20). Obesity had been consistently associated with 
higher risk of colorectal cancer in men (relative risks of approximately 1.5-2.0) 
and women (relative risks of proximately 1.2-1.5) in both case-control and cohort 
studies (21). Adiponectin, also called adipocyte complement-related protein 
(Acrp30), is a cytokine secreted from mature adipocyte. Adiponectin acts as an 
insulin-sensitizing hormone (22, 23) but also has anti-inflammatory (24) and anti-
atherogenic effects (25, 26). Unlike leptin and TNF-α, circulating adiponectin 
levels are decreased with increasing adiposity (27, 28). Low levels of adiponectin 
may thus provide a link between obesity and risk of colorectal cancer.  
Consequently, in our first study, we investigated whether the increased tumor 
susceptibility of ApcMin/+ mice on high calcium diet was due to the substantial loss 
of adipose tissue. Secondly, we designed experiments to evaluate the inhibitory 
effect of human adipocytes on Caco-2 cell proliferation in vitro. We also 
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1. Colorectal cancer: general aspects 
1.1 Prevalence of colorectal cancer 
    Colorectal cancer is the 3rd most common cancer worldwide and the second 
most common cause of cancer death in men and women, with an estimated 
112,340 new cases of colon cancer and 41,420 new cases of rectal cancer in 2007 
in the United States. Combined, they will cause about 52,180 deaths (1). Men and 
women are affected almost equally, with over 1 million cases annually diagnosed 
worldwide (2). Typically the rates of colon cancer incidence tend to be higher in 
developed countries. The highest rates of incidence are in North America, 
Australia, and New Zealand, whereas the lowest rates are in Africa, Asia and 
Latin America (3). Schottenfeld’s study showed that the risk of colon cancer 
increases in migrants after a period of 20-30 years following migration to a high-
risk country, and that the risk of developing colon cancer decreased after 
migrating from a high-risk area to a low-risk country (4).  
 
1.2 Risk factors 
1.2.1 Non-dietary factors 
    Age is a risk factor for the development of colorectal cancer, with 90% of 
colorectal cancer patients being over the age of fifty; however, risk is also 
increase in younger individuals who had a previous adenomatous polyp, or a 
history of clinical bowel inflammation (3). According to European Network of 
cancer Registries, in Europe, about 70% of patients with colon cancer are over 65 
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years of age. Colon cancer is rare under the age of 45. In the age group 45-54 
colon cancer incidence is about 20 per 100,000 per year and thereafter increases at 
a much higher rates (55 per 100,000 per year for aged 55-64, 120 for aged 65-74 
and 200 per 100,000 per year for those older than 75 years of age) (5).     
    Smoking has been consistently associated with adenomatous polyps. In the 
United States, about one in five colorectal cancer cases in men and about one in 
eight colorectal cancer cases in women may be due to smoking (6). Smoking 
seems to influence the early stages of the process, when normal cells become 
cancerous. One study has suggested that smoking early in life is likely to increase 
risk of colon cancer, and approximately 20% of the colon cancers in men appear 
to be attributable to smoking (7). Recent studies show that smokers are 30% to 
40% more likely than nonsmokers to die of colorectal cancer. 
    Many research studies have found people who have a high body mass index 
(BMI) are at an increased risk of colorectal cancer. Any additional weight above 
the healthy range appears to increase the risk of colorectal cancer. Some evidence 
indicated that a tendency to store fat in the abdominal area may also increase the 
risk of colorectal cancer. These will be discussed in detail below.  
    Race may be another risk factor for developing colorectal cancer. For example, 
colorectal cancer rates are lowest for Hispanics, while African Americans, both 
men and women, have the highest incidence and mortality rate. The five-year 
survival rate is much lower among African Americans than Whites (2). The 
reason for this racial difference is unclear and need to be studied further to better 
establish the underlining causes.   
 10
 
1.2.2 Dietary factors 
    Diet appears to be the most important exogenous factor identified in the 
etiology of colon cancer. It has been estimated that 70% of colorectal cancer 
could be prevented by nutritional intervention (8). Case-control studies have 
identified both promoting and protective factors. Generally, high vegetable, low 
fat diets have been associated with a lower risk of colorectal cancer.  
    Vegetables and fruits contain a large array of substances, both micronutrients, 
such as carotenoids, folate and ascorbate; and phytochemicals, such as phenols, 
flavonoids, isothiocyanates, and indoles. Vegetables are also rich in fiber. Early 
evidence indicated that diets rich in vegetables and fruits substantially protect 
against colon cancer. In a recent review by Steinmetz and Potter (9), 15 of the 21 
case-control studies examined showed statistically significant inverse associations 
between one or more vegetable/fruit categories and colon cancer risk. Four of the 
studies did not show significant inverse associations for any vegetable/fruit 
category, and in two studies statistical significance was not reported. Steinmetz 
and Potter also concluded that the protective effect of vegetables seemed to be 
most clear for raw vegetables vs. cooked and the green vs. yellow/orange 
vegetables. However, recent intervention and prospective studies of colorectal 
adenoma recurrence and colorectal cancer have not found protective associations, 
resulting in skepticism regarding the independent role of plant foods in cancer 
prevention (10-13). For instance, in the Netherlands Cohort Study on Diet and 
Cancer (12), the authors use a validated 150-item food frequency questionnaire. 
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After 6.3 years of follow-up (1986–1992), over 1,000 incident cases of colorectal 
cancer were registered. Using case-cohort analysis, the authors concluded that for 
colon cancer, no statistically significant associations with total vegetable intake or 
total fruit intake were found. However, among women, an inverse association was 
observed with vegetables and fruits combined (for the highest quintile vs. the 
lowest, the rate ratio (RR) was 0.66 (95% confidence interval (CI): 0.44, 1.01)). 
For rectal cancer, no statistically significant associations were found for vegetable 
consumption or fruit consumption or for specific groups of vegetables and fruits; 
only Brassica vegetables showed an inverse association in women. Another 
example is a large, prospective study in older Americans (13), the authors 
concluded that neither whole grain, fruits and vegetables, nor fiber consumption 
was independently associated with risk of incident colon cancer. Among men, 
consumption of vegetables, or a great variety of vegetables, was associated with a 
marginally lower risk of developing colon cancer, though this was not significant.  
    The term “dietary fiber” encompasses a complex mix of mostly non-digestible 
plant materials with variable effects on gastrointestinal physiology (14). The 
concept that a diet high in fiber, especially from fruits and vegetables, lowers risk 
of colorectal cancer has been around for more than four decades, starting from the 
observation that certain groups of people in Africa who eat a high-fiber diet also 
have low rates of colorectal cancer (15). Since this original idea, the relationship 
between fiber, fruits and vegetables in general, and colorectal cancer risk has been 
evaluated, with somewhat conflicting results. Some studies suggest that fiber can 
reduce risk, while others have found no effect. For example, the result from a 
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large cohort European study on diet support role of fiber as a protective factor for 
colon cancer (16). A large female cohort from the Women’s Health Study 
indicated that high intake of legume fiber was associated with a lower risk of 
colorectal cancer (RR=0.60, 95%CI: 0.40, 0.91, p=0.02) (17). The beneficial 
effect of dietary fiber was suggested to be a consequence of the ability of fiber to 
bind and reduce the concentration of bile acids in fecal water (18). Nevertheless, 
recent epidemiological data tended not to support this influence. One recent 
prospective study of fiber and colon cancer risk (13) reported that high intake of 
fiber was not related to lower risk of colon cancer, and this null finding is 
consistent with several other prospective studies (19-22).  
    The relationship between alcohol intake and colorectal cancer risk has been 
controversial, but the majority evidence now indicates that consuming large 
amounts of alcohol increases the risk of colorectal cancer (23). More recently, 
investigators have addressed this hypothesis using data from the Pooling Project 
of Prospective Studies, which combined data from eight large prospective studies 
(24). In the pooled analysis, compared to nondrinkers of alcohol, individuals who 
consumed 30 to 45 g/d of alcohol had a multivariate relative risk of 1.16 (95% CI: 
0.99, 1.37) and those who consumed 45 g/d of alcohol had a multivariate relative 
risk of 1.42 (95% CI: 1.16, 1.73). Alcohol was not related to risk among those 
who took multivitamins, most of which contain folic acid. In general, risk of both 
proximal and distal colon cancers and rectal cancer appear to be increased by high 
alcohol intake, although the reason for this increased risk is not entirely clear. 
Meat consumption has been associated with colorectal neoplasia in the 
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epidemiological literature, but the strength of the association and types of meat 
involved have not been consistent. World Cancer Research Fund (WCRF) 
indicated that red meat “probably” and processed meat “possibly” increases risk 
of colon cancer (23). Case-control studies of colorectal cancer conducted in the 
United States and European have generally reported the increased risk of colon 
cancer associated with red or processed meat (25, 26). Results from another 
prospective study of American women showed no evidence of an association 
between meat and colorectal cancer (27), which is consistent with the conclusion 
made from previous studies (25). More recently, results of the Cancer Prevention 
Study II Nutrition Cohort (28) showed that prolonged high consumption of red 
and processed meat might be associated with an increased risk of cancer of the 
distal portion of the large intestine; however, the increase was not statistically 
significant. The mechanisms underlying the association between colorectal cancer 
risk and high intake of red and processed meat are uncertain. Controlled human 
intervention studies have raised the possibility that the endogenous nitrosation 
that arises from ingestion of heme iron may account for the increased risk 









2. Dietary calcium and colorectal cancer 
    The adequate intake (AI) for calcium in adults of 19-50 y and 50-70 y are 1,000 
and 1,200 mg/day respectively. However, many people in the United States do not 
consume recommended levels of dietary calcium. According to the National 
Health and Nutrition Examination Survey from 1999-2000 (NHANES), median 
calcium intake for men ages from 19 to 50 years was approximately 900 mg/day, 
for women was about 800 mg/day, which is approximately 70% of the AI for that 
age group (31). Continuing Survey of Food Intakes by Individuals 1994-1996, 
1998 (CSFII 1994-1996, 1998) and NHANES 1999-2000 data both show that 
African Americans in all age groups have lower mean intakes of calcium than 
non-African Americans in both men and women (31). Low calcium intake is 
related to various chronic diseases. In addition to skeletal disorders, calcium 
deficit increases the risk of malignancies, particularly of colon, breast and prostate 
gland, of chronic inflammatory and autoimmune diseases, as well as of metabolic 
disorders (metabolic syndrome, hypertension) (32).  
 
2.1 Epidemiology 
    Calcium and calcium-containing foods have been evaluated in numerous 
studies of colon cancer. Ecological studies are the first epidemiological evidence 
to examine the associations between colorectal cancer rates occurred in different 
populations and their corresponding dietary habits. When the data for milk or 
milk product consumption is plotted against colorectal cancer mortality, it 
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emerges that per capita consumption of milk or milk products is inversely 
associated with mortality of colorectal cancer (33). Sorenson et al (34) have noted 
that the areas in rural Finland, where calcium consumption is high, have one of 
the lowest colon cancer incidence rates among the developed countries, whereas 
Helsinki has a higher incidence rate and a lower level of calcium intake. 
Traditionally, ecological studies are useful, but because they do not consider other 
factor, such as environmental and lifestyle variations, which limit conclusions 
regarding the relationships between milk or calcium consumption and colorectal 
cancer.  
    The analytical observational epidemiological literature on the association of 
calcium and colon cancer is somewhat inconsistent, but inverse associations have 
more frequently been found (35-45). The first long-term prospective study of the 
association of dietary calcium and vitamin D and the risk of colon cancer was 
reported by Garland and coworkers (46). After a 19-year prospective study of 
1965 men in Chicago, they found a strong inverse correlation between colorectal 
cancer risk and dietary vitamin D and calcium intake. Early prospective effect of 
calcium was also described from case-control studies in the Southwest United 
States (47) and in Australia (48). In 1988, Sorenson et al summarized all of these 
studies and emphasized the inverse relationship with calcium consumption in age-
adjusted colon cancer incidence rates (49). Recent epidemiologic evidence, 
including 7 cohort studies of colorectal cancer (35-37, 39-41, 45) and 3 case-
control studies (38, 42-43), generally reported inverse associations between 
calcium intake and overall risk of colorectal tumors, and suggested a 30-40% 
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reduction in risk at high levels of intake (35-37). Cho et al (44) pooled 10 
prospective studies in a meta-analysis and reported that calcium intake was 
inversely related to the risk of colorectal cancer. The relative risk (RR) for the 
highest versus the lowest quintile of intake was 0.86 (95% CI: 0.78, 0.95; 
Ptrend<0.02) for dietary calcium and 0.78 (95% CI 0.69 to 0.88; Ptrend<0.001) for 
total calcium (combining dietary and supplemental sources).  
In the United States, colon cancer cases in the left-sided or distal colon 
constitute about two-thirds of all colon cancer cases (54). A protective effect of 
higher dietary calcium intake against colon cancer has been reported for more 
distal colon tumors than proximal and rectum tumors (36, 44, 50, 51-53). In the 
cohort study of women done by Terry et al (36), calcium was inversely associated 
with distal colon RR=0.45, 95% CI: 0.26, 0.79) and rectal cancer (RR=0.70, 95% 
CI: 0.45, 1.09). In Peters’ study (50) the protective associations were strongest for 
tumors of the distal colon, with no association between calcium and rectal tumors. 
In contrast, in the Cancer Prevention Study II Nutrition Cohort (37), a high total 
calcium intake was related to a reduced risk of proximal colon cancer, but not of 
distal colon and rectal cancer. In other epidemiologic studies, associations 
between calcium intake and rectal tumors were equivocal, with some studies 
showing significant protective associations (43, 55), and with others showing 
statistically non-significant protective associations (56, 57).  
    Although a protective effect of dietary calcium is suggested by many studies, 
such a relationship is not found in all studies. Observational epidemiologic studies 
published through the mid-1990s provided no strong support for a protective 
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association between calcium intake and colorectal cancer risk (58, 59). A recent 
cohort study conducted in women also reported no association (60). Studies that 
showed no significant inverse association with calcium were generally limited by 
a relatively small sample size and thus were underpowered to detect risk 
reductions. In addition, inaccurate recall of dietary and supplemental intake might 
not reflect the usual intake during the observation period, resulting in an 
attenuated calcium-colorectal cancer association.  
    Thus, although there is animal and epidemiological support for the hypothesis 
that higher calcium consumption may contribute to a modest reduction in the risk 
of colon cancer, clinical trials will be needed to ultimately fully address the 
hypothesis.  
 
2.2 Intervention trials 
It is extremely difficult to conduct randomized controlled trials of sufficient 
size and duration to isolate the protective effect of any nutritional supplement 
(61); consequently, it is generally necessary to rely on biomarkers and 
intermediate end points. Two major different end points have been used as 
intermediate biomarkers of risk in colorectal neoplasia. An early intermediate 
biomarker is colorectal epithelial cell proliferation. A late intermediate biomarker 
of risk is the formation of adenomatous polyps, which usually have been 
investigated in volunteers who have previously had adenomatous polyps and 




2.2.1 Human trials of calcium and colorectal epithelial cell proliferation 
 
    Incubation techniques and methods that measure endogenous markers with 
DNA synthesis have been used to determine proliferating cells in the laboratory 
(62). The most commonly used methods of measuring colorectal epithelial cell 
proliferation are the H3-thymidine method (63), the bromodeoxyunidine (BrdU) 
method (64), and the proliferating cell nuclear antigen (PCNA) method (65). H3-
thymidine method is very sensitive and the disadvantages are dealing with 
radioactive material and time consuming. Alternatively, incubation with BrdU has 
been used. In the PCNA method, no incubation and incorporation of a labeling 
agent are required, but PCNA method has been criticized for being more difficult 
to count, because the method yields cells that are labeled to varying intensity. 
    Regardless of which method has been used in measuring proliferating cells, 
there is controversy regarding the effect of calcium supplements upon 
proliferation. The early studies of calcium administration showed statistically 
reduced labeling indices. Lipkin and Newmark reported the first human study of 
the effect of calcium administration upon the colon in 1985 (66). In that 
uncontrolled study, administration of 1,250 mg of elemental calcium to subjects 
with a familial history of sporadic adenomas resulted in pronounced changes in 
cell proliferation. In the following several years, a series of studies (67-69) 
supported that supplemental dietary calcium decreased hyperproliferation of 
colonic epithelial cells. Buset’s research (67) on 9 patients at risk of developing 
colorectal cancer who were supplemented with 1,500 mg/d of calcium for 4-8 
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weeks concluded that this calcium intervention inhibited the proliferation of 
colonic epithelial cells. Moreover, each colonic mucosal biopsy exhibited a 
decrease in proliferation when they were cultured in vitro with a high level of 
CaCl2. Further evidence was obtained in a similar experiment done by Lipkin in 
1989 (69). 
    In the past two decades, some studies confirmed that dietary calcium could 
decrease colonic epithelial cell proliferation (70-73). For instance, Bostick’s study 
(72) was carried out on patients at increased risk of colon cancer and found that 
calcium supplementation decreased the size of the proliferative compartment in 
the colonic crypts. Holt et al (73) also designed a randomized, single-blinded trial 
to determine whether increasing dietary calcium via low fat dairy food altered 
colonic biomarkers toward normal, and reported that increasing calcium up to 
1,200 mg/d in subjects at risk for colonic neoplasia reduces the epithelial cell 
proliferation activity. However, other studies could not confirm this effect (74-
78). Van Gorkom (74) performed a randomized controlled trial in 86 patients (28 
treated with placebo and 30 with calcium + placebo). Epithelial cell proliferation 
was determined by dividing the number of 5-bromo-2-deoxyuridine labeled nuclei 
by the total number of nuclei ×100 (labeling index, LI). No difference was 
observed in total LI. They concluded that colonic epithelial cell proliferative 
activity throughout the colon of sporadic adenoma patients is not affected by 
supplementation with 1 g of calcium. In double-blinded, placebo-controlled 
randomized trials, neither Armitage et al (75) nor Alberts and coworkers (77) 
found a significant effect of calcium carbonate supplements on cellular 
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proliferation rates in colon mucosal biopsies. Therefore, Bostick (79) concluded 
that the combined results of all of the published studies of calcium 
supplementation and colorectal epithelial cell do not support the hypothesis that 
calcium supplementation reduces the rate of proliferation of the colon epithelium 
in humans.   
    Several reviews have discussed the reason for the inconsistency in the literature 
regarding the effects of oral calcium on colonic epithelial cell proliferation (79-
81). Possible explanations include the uncontrolled nature of the early studies and 
the sample size as related to the clinical importance of the estimated treatment 
effect. Variations in sample size may cause the bias in the results. For example, 
Van Gorkom’s trial (74) was conducted with 15 patients, and Buset’s work 
included only 9 patients, whereas in some studies, the sample size was 
approximately 100 patients (78). Furthermore, there are many methodological 
problems that have been recognized. As mentioned in Bosick’s review, the 
different trials took biopsies for cell proliferation measurements at different time 
points from one another. The studies also differed on use of bowel preps and the 
different studies use different laboratory methods for assessing cell proliferation. 
Thus, attempts are being made to improve the standardization of the population 
studied and the methods with which the assay end points are measured.  
    The conflicting evidence on the question whether dietary calcium does reduce 
colonic epithelial cell proliferation raises two key questions: (1) Is cell 
proliferation a good biomarker to examine the effect of dietary calcium on 
colorectal cancer risk, and (2) Is calcium supplementation a potential intervention 
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to reduce the risk of colorectal cancer? 
2.2.2 The effect of dietary calcium on colorectal adenomatous polyps 
The proliferative index does not appear to be a reliable predictive tool for 
future colorectal neoplasia, and Sandler (82) has suggested that adenomas serve as 
a better-proven and more reliable intermediate. Since almost all colorectal cancers 
develop from adenomas, and 5% of all adenomas develop into cancer (83), studies 
regarding the development of colorectal adenomatous polyps as an end point may 
be reasonable. Many clinical trials have been done to investigate the effect of 
dietary calcium on adenomatous polyps (84-91). Since it is difficult to conduct a 
randomized controlled trial large and long enough to observe the protective effect 
of dietary calcium, so far only two groups have succeeded in completing such 
trials. Baron described the first study of calcium prevention of adenomatous polyp 
recurrence in 1999 (84). They randomly assigned 930 subjects (mean age, 61 
years; 72 %  men) with a recent history of colorectal adenomas to receive either 
calcium carbonate (3 g (1,200 mg of elemental calcium) daily) or placebo, with 
follow-up colonoscopies one and four years after the qualifying examination. The 
adjusted risk ratio for any recurrence of adenoma with calcium as compared with 
placebo was 0.85 (95 % CI: 0.74, 0.98; p=0.03). The adjusted ratio of the average 
number of adenomas in the calcium group to that in the placebo group was 0.76 
(95 % CI: 0.60, 0.96; p=0.02). Shortly after the first paper was published, a 
second randomized trial was done in 2000 (85), with 665 subjects with a previous 
history of colorectal adenoma; this study compared 3-arms: calcium 2,000 mg, 
fiber 3,500 mg and placebo group. The calcium group showed a significant 
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reduction for adenoma recurrence, odd ratio (OR)=0.66 (95% CI: 0.38, 1.17). 
Calcium supplementation for three years gave a modest reduction in the risk of 
adenoma recurrence. Similar to these two large clinical trials, other studies 
observed a decreasing risk of colorectal adenoma with an increasing intake of 
calcium (87-91).     
 
2.3 Mechanisms behind the inhibitory effect of dietary calcium on colorectal   
 
      cancer risk 
 
2.3.1 Reduce the cytotoxicity of fecal water 
 
    The mechanism through which calcium may prevent colorectal cancer is not 
certain. One major hypothesis from Harold Newmark and coworkers (92) is that 
fatty acids and bile acids are the colonic components most responsible for 
inducing epithelial cells in the direction of carcinogenesis. They also emphasized 
that colonic fatty acids and bile acids would need to be in the aqueous phase of 
colonic contents in order to interact with the colonic mucosa and to stimulate 
pathogenic changes. They then postulated that if an excess of calcium entered the 
colon, then soluble bile acids and fatty acids would be precipitated and therefore 
no longer are able to alter the epithelium. This calcium precipitation of cytotoxic 
substances in feces hypothesis was confirmed in both human and animal studies. 
Van der Meer and coworkers (93) studied the fecal composition of 12 volunteers 
who fed either a regular diet or regular diet supplemented with 35 μM of 
inorganic calcium per day in a crossover experiment. They demonstrated that the 
provision of supplemental calcium increased the amount of calcium appearing in 
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the stool when compared to volunteers not taking supplement calcium. The bile 
acid output increased by 35%, and there was a shift of the bile acid composition to 
an increased ratio of trihydroxy to dihydroxy bile acids. They then concluded that 
calcium would reduce damage to the colonic epithelium from fecal water. The 
same group did another experiment in rodents (94). They added low-fat dried 
milk powder to a Western-style diet in rodents and showed a similar reduction in 
the cytolytic activity of reconstituted fecal water. Later they fed volunteers with 
dairy calcium in dried powdered milk daily. The high milk calcium diet 
significantly decreased the cytotoxicity of fecal water from 68% to 28% (95). 
Calcium also has been shown to reduce the colonic content of diacylglycerol 
formed by bacteria, which may activate cellular transduction pathways and has 
been postulated as increasing proliferation in the colonic epithelium (96).  
 
2.3.2 Inhibit epithelial cell proliferation  
    Another hypothesis is that calcium might directly influence proliferation by 
inducing cell differentiation. As cancer is predominantly a disease of disordered 
balance between proliferation, differentiation, and apoptosis, disruptions in the 
function of the calcium-sensing receptor (CaR) could contribute to the 
progression of neoplastic disease. (97). CaRs have been identified in human colon 
cancer cell lines (98, 99) and malignant mucosa of the large intestine (100). 
Furthermore, immunohistochemical studies of human colon carcinomas indicated 
that CaR protein was most highly expressed in well-differentiated regions of the 
tumor and nearly lacking in poorly differentiated regions (100, 101). These data 
 24
suggest that expression of functional CaR may contribute to the progression of 
colon carcinomas. The activation of CaR in colon epithelial cells is followed by 
the activation of protein kinase C (PKC). Early study by Weinstein (102) has 
shown that in human colonic mucosa total PKC activity was reduced compared to 
normal colonic tissues. Frey et al (103) have shown that PKC signaling is 
involved in a program of cell cycle withdrawal in intestinal epithelium associated 
with down-regulation of cyclin D1 and differential induction of the p21waf1/cip and 
p27kip1 inhibitors of cyclin-dependent kinase (CDK) activity. Therefore, PKC 
activation through CaR provoked by dietary calcium may be critical for its 
antiproliferative, differentiation-inducing effects on human colon epithelial cells.  
 
2.3.3 Target prostaglandin (PG) pathway 
Cyclooxygenase-2 (COX-2) is an inducible enzyme that regulates 
prostaglandin synthesis and is over-expressed in animal models of colon 
carcinoma (104-106). Studies have elucidated the regulation of COX-2 expression 
and have identified prostaglandin E (PGE2) receptors through which prostanoids 
exert their biological effects (105). COX-2-derived primary PG generated in 
colorectal tumors, PGE2, is known to stimulate cell migration, proliferation and 
tumor-associated neovascularization while inhibiting cell death. A very recent 
study indicates that calcitriol inhibits the PG pathway in prostate cancer cells by 
decreasing COX-2 expression and PGE2 receptors (107). Thus, calcitriol may be 
an attractive therapeutic option for the treatment of colorectal cancer.  
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2.4 Dairy food and colorectal cancer 
    Both case-control studies and prospective studies pointed out that milk is the 
individual dairy food with the strongest influence on colorectal cancer risk (108). 
Larsson et al (109) in their Cohort of Swedish men Trial fount that colorectal 
cancer is influenced by total dairy food consumption (multivariate rate ratios 
(RRs) was 0.46). The effect of milk also reaches the significance (RR was 0.53.). 
A pooled analysis of ten cohort studies carried out by Cho et al (44) suggested 
that milk was inversely related to colorectal cancer. Compared with participants 
who consumed less than 70 g of milk per day, the relative risk (RR) for colorectal 
cancer was 0.85 (95% CI: 0.78, 0.94) for those who consumed 250 g/d or more. 
Other dairy foods (cheese and yogurt) have been analyzed, but there was no 
statistical significance with relation to colorectal cancer risk.  
In addition to the calcium content in the dairy foods, other factors, such as 
conjugated linoleic acid, sphingolipids, butyric acid and milk proteins, have been linked 
to a reduction in colon cancer.  Growing evidence indicate the impact of vitamin D 
status on the interaction between calcium intake, dairy intake and colon cancer risk. 
Animal studies showed that dietary calcium and vitamin D status were co-modulators 
of colon cancer and that vitamin D deficiency abolished the protective effects of 
calcium on tumor formation (110). Cho et al (44) presented data suggesting that the 
benefit of higher calcium intake may depend on high vitamin D intake. Given that 
vitamin D status might modulate effect of calcium on colon cancer risk, measurement 
of plasma levels of 1,25-(OH)2 vitamin D and 25-(OH) vitamin D may generate a 
better testing of hypothesis on the roles of milk in colon cancer etiology.   
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3. Pathology and biology of colorectal cancer 
3.1 ACF-Adenoma-Carcinoma sequence  
    The definition of an adenoma-carcinoma sequence in colorectal cancer (CRC) 
was first made by Basil Morson (111). This theory states that there is a 
progressive mutation of oncogenes and loss of the function of tumor suppressor 
genes (112), and the pattern of change that occurred in certain genes in colorectal 
cancers might be reflected in the different stages in development of tumors during 
the transition from normal mucosa to polyp and subsequent cancer (Fig.1). Thus, 
APC mutations occurred in early adenomas, while, mutations in the p53 gene 
occurred later in the sequence, although prior to metastasis. The mutated genes in 
CRC include those involved in the Wnt pathway, namely APC, and β-catenin, 
genes involved in apoptosis including p53 and the mismatch repair genes, human 
mutL homolog 1 (hMLH1), human mutS homolog 2 (hMSH2) and human mutS 
homolog 6 (hMSH6), cell cycle check point genes such as p14, p16 and genes for 
growth factors, their receptors and signaling (TGFβ-receptor 2, Smad4, K-ras) 
(113).  
    The earliest identifiable lesion in colon cancer formation is the aberrant crypt 
focus (ACF). The crypts are larger or longer than normal crypts with no stratified 
and depolarized nuclei (114). The investigation of ACF by using 25 different 
genetic markers, such as microsatellite instabilities and mutations of APC, H-ras, 
K-ras, p53, deleted in colorectal carcinoma (DCC), and DNA repair genes 
hMLH1, hMSH2, showed no difference between hyperplastic ACF and normal 
mucosa (115). In dysplastic ACF, both crypts and cells have different degree of 
abnormalities, with enlarged, elongated and sometimes stratified and depolarized 
nuclei. It has similar histopathological manifestations of adenomas (116). 
Dysplastic ACF does appear to harbor mutations in K-ras or APC. If a ras gene 
mutation occurred first, ACF would not be dysplasia, and if an APC mutation was 
the first to occur, such as familial adenomatous polyposis (FAP), it would result 
in a dysplastic ACF, whose progression was driven by subsequent K-ras and other 
gene mutations (117). Thus, alterations in APC, which result in over-activation of 
the Wnt signaling pathway (discussed below), appear to initiate tumor formation 
in the colon. Subsequent alterations in other genes play a role in tumor growth 
and tissue invasiveness. 
 3.2 Genetic basis in colorectal carcinogenesis 
    It is now accepted that colorectal cancer develops by genetic alterations. These 
alterations do not directly affect the cell biology of the tumor, but result in loss of 
genomic stability, which contributes to the accumulation of mutations in tumor 
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suppressor genes and oncogenes (118). There are two major pathways in 
colorectal carcinogenesis. One is the chromosomal instability pathway (CIN), and 
the other is a pathway involving microsatellite instability (MSI). 
 
3.2.1 Chromosomal instability pathway  
    This pathway is characterized by allelic losses on chromosome 5q (APC), 7p 
(p53), and 18q (DCC/Smad4), and is therefore called the chromosomal instability 
(CIN) pathway (119). CIN pathway is a model represented by FAP, which is 
following ACF-adenoma-carcinoma sequence, that is, one germline mutation and 
one somatic mutation in the APC gene, followed by mutations of K-ras, and 
subsequently mutations of p53 and deletion on chromosome 18q.  
 
APC gene 
    Mutations in the APC gene on human chromosome 5q21 locus are considered 
as one of the earliest events in the initiation and progression of colorectal cancer. 
Loss of APC caused by mutations in both alleles was found in a majority of FAP 
patients as well as in > 80% of sporadic CRCs and adenomas (120).  
    Many APC mutations have now been identified, both in the germ line in FAP 
patients, and somatically in sporadic CRCs. The classical mutations happened 
between codons 178 and 309 and between codons 409 and 1580, that is exons 5-8, 
9-14 and the first half of exon 15 (121). In DNA sequence of APC, the most 
important functional domains of the APC gene appear to be the first serine alanine 
methionine proline (SAMP) (axin binding) repeat at codon 1580 (122) and three 
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20-amino acid repeats (20AARs) involved in β-catenin binding and degradation. 
The great majority of pathogenic APC mutations truncate the protein before the 
first SAMP repeat and leave a stable, truncated protein that encodes 0–3 20AARs. 
    It had been known for some years that somatic APC mutations tend to occur in 
a restricted region of the gene mutation cluster region (MCR) that lay 
approximately between codons 1250 and 1450 (123). In particular, it has been 
shown for both sporadic tumors and tumors in FAP patients that, when the first 
mutation is in the MCR, then the second event leads to loss of the normal function 
of the APC gene is due to loss of heterozygosity (LOH), mainly as a result of 
mitotic recombination. On the other hand, when the first mutation is not in the 
MCR, then the second event is a further mutation in the MCR. This implies that 
there is a selective advantage for mutations in the MCR (121).  
    The APC gene has 15 exons and encodes a large protein (310 kDa, 2843 amino 
acids) that possesses multiple functional domains that mediate binding to a variety 
of intracellular proteins including β-catenin, γ-catenin, glycogen synthase kinase 
(GSK)-3β, axin, tubulin, and end binding protein (EB1) (124). The best-
characterized function of APC is as a scaffolding protein in a multi-protein 
complex and its activity is modulated by Wnt signaling (125). This complex 
regulates the phosphorylation of β-catenin and thus controls the amount of β-
catenin available for transcriptional activation via T cell factor and lymphoid 
enhancer factor (TCF/LEF) transcriptions factors. Other proteins that are part of 
this complex include GSK-3β, β-catenin, axin and several kinases and 
phosphatases. A number of reviews have described the details of this pathway 
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(125-127). Briefly, in the absence of extracellular Wnt signals, GSK-3β in the 
APC-β-catenin-axin complex is active, phosphorylating its serine and threonine 
residues and all three of these proteins and increases their interaction. In this way, 
phosphorylated β-catenin is for subsequent degradation by ubiquitin-mediated 
proteolysis. Downregulation of β-catenin is dependent on the presence of at least 
three of the seven 20AARs.  
    Truncated mutations of APC that lack all or most of the 20AARs are unable to 
bind β-catenin. Therefore, β-catenin cannot be phosphorylated and broken down.  
Accumulation of β-catenin within the cellular cytoplasma and nucleous associates 
with members of the TCF/LEF transcriptions factors and activates the expression 
of a variety of genes that can change the proliferation and differentiation state of 
cells, including those encoding cyclin D1, c-myc, and c-jun (128-130). However, 
there are additional pathways that contribute to the regulation of β-catenin and are 
independent of APC and other proteins involved in the Wnt pathway (131). These 
include the p53-inducible Siah-1 protein (132) and a retinoid X receptor (RXR) 
(133). Besides the Wnt pathway, other functions of APC are also involved in 
colorectal carcinogenesis.  
    APC mutation can affect actin cytoskeletal integrity, which is necessary to 
maintain the shape and adherence junctions of cells. The link of APC with actin is 
through β-catenin. β-catenin establishes this link by providing a bridge to α-
catenin (134). The imbalances in actin cytoskeletal integrity can disturb cell-cell 
adhesion and cell migration, which play a role in the initiation of colon cancer.  
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    Interaction of APC with β-catenin and adhesion complex has been implicated 
in cell-cell adhesion (135). The accumulation of β-catenin caused by truncated 
APC protein can bind to the TCF/LEF transcription factor, and down-regulate the 
transcription of E-cadherin gene expression. These complex interactions may 
finally result in the reduction in E-cadherin-mediated cell-cell adhesion and 
proliferation of cells (136, 137).  
    Another important role for APC is in cell migration. Colonic epithelial cells, 
derived from a stem cell, divide in the lower two-third of the crypts and migrate 
rapidly to the surface to form a single layer. The function of a wild-type APC is 
necessary in maintaining the direction of upward movement of these cells along 
the crypt-villus axis. Loss of wild-type APC functions affects cell migration. 
These cells, instead of migrating upwards towards the gut lumen, migrate 
aberrantly or less efficiently towards the crypt base where they accumulate and 
form polyps (138). The mechanisms by which APC might be involved in cell 
migration can be understood by its association with microtubules, EB1, IQ motif 
containing GTPase activating protein 1 (IQGAP1), APC-stimulated guanine 
nucleotide exchange factor (ASEF) and kinesin superfamily-associated protein 3 
(KAP3) (139). For example, an interaction of APC has been shown with ASEF 
that may regulate the actin cytoskeletal network (140). Another example is APC 
binding with ASEF and controls its activity. ASEF is activated in colorectal 
cancer cells containing truncated APC. Active ASEF decreases E-cadherin-
mediated cell-cell adhesion and promotes inappropriate cell migration.  
    APC is also a cell cycle regulator. Over-expression of APC is capable of 
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blocking cell cycle progression from G0/G1 to S phase (141). Matsumine’s study 
(142) indicated that APC-DLG complex might participate in regulation of cell 
cycle progression, because the APC-β-catenin complex was shown to bind to the 
human homolog of the Drosophila discs large tumor suppressor (DLG) protein. 
This interaction required the carboxyl-terminal region of APC and the DLG 
homology repeat region of DLG. Ishidate stated that mutant APC lacking the 
carboxyl-terminal S/TXV motif for DLG binding exhibits weaker cell cycle 
blocking activity at G0/G1 phase than the intact APC (143).  
    APC may play a role in regulating apoptosis. Venesio et al. reported that a 
germline mutation of APC on codon 1383, in the 20AARs of the β-catenin 
binding domain, found in some FAP patients resulted in decreased apoptotic 
level. This decrease is independent of a somatic alteration on the wild type allele 
(144). These findings suggest that mutations in critical sites of the β-catenin 
binding domain of APC gene can alter the apoptotic surveillance rather than 
enhancing the β-catenin-TCF/LEF transcription of growth-promoting genes. The 
regulation of apoptosis by APC may be an important part of APC's tumor 
suppressor function. However, the mechanism responsible for the regulation of 
APC-induced apoptosis is not understood, but several recent evidences support 
the involvement of clusterin (145) and survivin (146). Wnt signaling pathway 
may also be involved in the increased apoptosis induced by APC protein. 
Survivin, which is downregulated in response to APC expression, is also 
downregulated by dominant negative TCF4 (146). This finding supports the idea 





    β-catenin is a member of the APC/β-catenin/TCF/LEF pathway that plays an 
important role in the formation of colorectal cancer. Mutation of β-catenin often 
renders β-catenin insensitive to APC/β-catenin/GSK-3β mediated degradation. 
The majority of CTNNB1 mutations are missense mutations in the highly 
conserved exon 3, encoding for the GSK-3β phosphorylation region of β-catenin, 
result in the impairment of the ability of GSK-3β to phosphorylate β-catenin 
(147). Therefore, cancers with CTNNB1 mutations have increased β-
catenin/TCF/LEF mediated transcription, which leads to the overexpression of 
genes such as c-myc and cyclin D1 (130, 148).  
    Accumulating findings support the role of β-catenin in colon carcinogenesis 
(149-153). Roh et al. (150) reported that antisense-mediated down-regulated β-
catenin expression in APC-mutant human colon carcinoma cells inhibits the in 
vitro cell proliferation and cellular invasiveness. Wang’s study (151) showed that 
in excessive cytosolic β-catenin, colonic cells become resistant to inflammatory 
factor nitric oxide-induced, p53-mediated apoptosis and survives with damaged 
DNA. This study suggested mutant β-catenin might contribute to human colonic 
carcinogenesis and tumor progression. In 1999, Harada et al. (149) constructed 
mutant mice that carried a dominant and stable β-catenin mutation, which was 
expressed in the intestinal and colonic epithelia. These mice developed numerous 
intestinal adenomatous polyps and some colonic microadenomas, which is similar 
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with a Min mouse phenotype. These results provide direct experimental evidence 
for the involvement of CTNNB1 mutations in Wnt signaling in colon tumor 




    Tumor suppressor genes are a class of genes with normal function that appear 
to be related to the control or suppression of cell proliferation. The inactivation of 
these genes caused by mutations resulted in the loss of normal cell growth control.  
    The tumor suppressor gene p53 is absent or mutated in 40%-50% sporadic 
colorectal cancers and 85% of all human colon cancers (154). This defect in p53 
tends to be a later event in colorectal carcinogenesis. Fazil et al. stated that the 
role of p53 might be the induction of apoptosis in response to mutations of APC, 
ras and other genes. Therefore, p53 is inactivated at a late stage of tumor 
development (155). p53 gene is located at 17p13.1. Wild-type p53 is currently 
believed to be involved in maintaining genomic stability through the control of 
cell cycle progression and apoptosis in response to the genomic stress (156). Its 
expression level is very low in cells until it is activated by DNA damages such as 
ultraviolet irradiation or chemotherapeutic agents. Several studies suggested that 
wild-type p53 could induce apoptosis in colorectal cancer cells (157-160). Shaw’s 
study (157) revealed that cells expressing wild-type p53 developed morphological 
features of apoptosis. DNA from both attached and detached human colon-
derived cells was degraded into a ladder of fragments. Further molecular 
biological studies show that p53 levels are suppressed by Bcl-2 (159). 
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Additionally, a recent study suggests that p53 stimulates apoptosis by suppressing 
the level of survivin (160).  
 
K-ras 
        K-ras is the best-studied and most common oncogene involved in colorectal 
carcinogenesis (161). K-ras mutations are detected in 58% of larger adenomas and 
47-50% of colorectal cancers (162). The majority of K-ras point mutations occur 
at codons 12, 13, and 61 (163, 164). Mutated K-ras appears to be capable of 
stimulating Wnt signaling in colon cancer through suppression of GSK-3β (165), 
as well as RAF/MAPK, JNK, and phosphotydylinositol 3-kinase (PI3-kinase), 
leading to constitutive growth promotion. 
    Another oncogene, cellular Src (c-Src) is a non-receptor protein tyrosine kinase 
whose activation is reported as an early event in the development of pre-
neoplastic colonic adenomas and also detected in >70% of colon carcinomas 
(166). In metastasis of experimental colon epithelial cells, over-expression of c-
src plays an important role by activating Akt/PKB-mediated survival pathways, 
which is leading to cell hyperproliferation (167).  
 
3.2.2 Microsatellite instability (MSI) pathway 
    MSI is characterized by expansions or contractions in the number of repeats of 
simple DNA sequences (microsatellites). It has been identified in colorectal 
cancer associated with hereditary nonpolyposis colorectal cancer (HNPCC) 
syndrome (168) and DNA mismatch repair (MMR) enzymes, including hMSH2, 
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hMLH1, hPMS1, hPMS2, and hMSH6, have been shown to be responsible for 
MSI.  
 
Mutation Mismatch Repair genes (MMR) 
    The DNA mismatch repair system (MMR system) consists of a complex of 
proteins that recognizes and repair base pair mismatches that occur during DNA 
replication. Inactivation of the MMR system due to germline gene defects 
accounts for the colon cancer family syndrome, HNPCC (169). HNPCC accounts 
for about 5%-7% of cases of colorectal carcinoma (170). The resulting colon 
cancer displays the phenotype of MSI, which is characterized by the size variation 
of microsatellites in tumor DNA as compared to matching normal DNA. 
    There are at least six different proteins involved in the MMR system have been 
identified in HNPCC. These proteins are hMSH2, hMSH3, hMSH6, hMLH1, 
hPMS1 and hPMS2. Recently, germline mutations in hMSH2 and hMLH1 genes 
have been suggested to cause early onset in colorectal cancer patients (171), and 
have been found in 45%-70% of HNPCC (172, 173). The germline mutations that 
occur in hMSH2 and hMLH1 are widely distributed throughout the gene. The 
mutations that occur in either gene tend to be point mutations that are single base-
pair substitutions, deletions, or insertions (174). Study of the biochemistry of the 
MMR proteins has revealed that hMSH2 forms a heterodimer with either hMSH6 
or hMSH3 and binds to the mismatch site. The complex of hMSH2 with hMSH6 
is required for the correction of single-base mismatches. The complex of hMSH2 
with hMSH3 is required for the correction of insertion-deletion loops (175). 
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Mutations in the hMLH1 and hPMS2 have been found in about 90% of HNPCC 
cases. Mutations in other MMR genes have been less frequent in HNPCC patients 
(169). 
    Mutation rate in cells with MMR deficiency are 100-1,000-fold greater than in 
normal cells, and the targeted genes particularly show instable microsatellite 
repeats in their coding regions (176). Indeed, many genes that possess 
microsatellite repeats are observed to be mutated in MSI colon cancers. Although 
MSI and the subsequent target gene mutations appear to occur throughout the 
adenoma-carcinoma progression, the precise stage of tumorigenesis in which 
mutation occurs is not clear. There are many targets of MMR gene inactivation. 
They include TGF-β receptor type 2 tumor suppressor gene (TGFBR2), insulin 
like growth factor 2 receptor (IGFIIR), Bcl-2-associated X protein (BAX) and 
caspase 5, the proteins that regulate apoptosis; E2F4 and TCF4, transcription 
factors; MSH3 and MSH6, DNA mismatch repair proteins; RIZ, the 
retinoblastoma protein-interacting zinc finger gene; and CDX2, an intestinal 
homeobox factor (177-181).  
     
TGFBR2 
    As much as 90% of the colorectal cancers with MSI have a TGFBR2 gene 
mutation. One mutation found in the TGFBR2 gene is that add or delete one or 
two adenine bases within or from 10 base-pair poly(A) repeat in the cysteine-rich 
coding region (codons 125–128). The other mutation in the TGFBR2 gene is 
located at poly(GT)3 with insertion of an extra GT in this region (177, 182). 
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These mutations produce truncated proteins that lack the cytoplasmic domain. In 
fact, alterations of TGFBR2 have been identified in up to 30% of colon cancers 
and are the most common mechanism identified to date for inactivating the TGFβ 
signaling pathway (177). It is known that TGFβ is a multifunctional cytokine that 
can induce growth inhibition, apoptosis, and differentiation in intestinal epithelial 
cells through regulating Type 1 plasminogen inhibitor (PAI-1) and cyclin 
dependent kinase inhibitor p15 genes expression. PAI-1 is the primary inhibitor of 
tissue type plasminogen activator (tPA) and urokinase-type 1 plasminogen 
activator (uPA), the products of which are implicated in the control of cell 
adhesion and invasion (183). Increased p15 expression, initiated by TGFβ, can 
induce G1-phase cell cycle arrest (184). Thus, the loss of TGFBR2 can abolish 
TGFβ-signaling and promote cell proliferation and development of colorectal 
cancer. In a study of colon cancer cell line HCT116 with a mutant TGFBR2 gene, 
investigators found that reconstitution of wild-type TGFBR2 suppressed the 
tumor phenotype of the cell line (185).   
  
IGFIIR 
    One of the microsatellites in the coding region of IGFIIR gene is poly(G) 
repeat which is often mutated with 1- or 2-base pair deletions or insertions. These 
mutations produce frameshifts and premature stop codons (186). IGFIIR plays a 
critical role in cell growth, survival and differentiation as a tumor suppressor; 
however, once mutated such as the loss of IGFIIR function due to mutations in 
MSI cells may enhance its proliferation due to accumulation and activation of 
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IGFII and down-regulation of TGFβ1, which are cognate ligands of IGFIIR, and 
thus play a major role in tumorigenesis (187). Souza et al. (188) transfected a 
zinc-inducible construct containing the wild-type IGFIIR cDNA into colon cancer 
cell line SW48, which has mono-allelic mutation in IGFIIR, and found that zinc 
induction of exogenous wild-type IGFIIR expression reproducibly decreased 
growth rate and increased apoptosis. These data prove that wild-type IGFIIR 
functions as a growth suppressor gene in colorectal cancer cells. A very recent 
study in APC (Min/+) mice (189) provides genetic evidence that the 
consequences of excess supply of IGF-II ligand can be rescued by soluble 
IGFIIR, and this supports the rationale application of this novel IGFII–targeted 
therapy for colon cancer. 
 
SMAD4 (MAD homologue 4 (Drosophila)) 
    Tumor suppressor gene SMAD4, also called DPC4 (deleted in pancreatic 
carcinoma, locus 4), is located at chromosome 18q where LOH occurs in 
approximately 70% of colon adenocarcinoma (190).  
    The SMAD proteins (R-SMADs) serve as intracellular mediators to regulate 
TGFβ signaling. In brief, TGFβ ligand binding with TGFBR2 recruits TGFBR1 
into a tetrameric receptor complex which results in transphosphorylation and 
activation of TGFBR1. After phosphorylation, the TGFBR1 becomes an active 
kinase to phosphorylate SMAD 2 and SMAD3. Phosphorylated SMAD2 and 
SMAD3 allow the formation of homo- and heterodimerization complex, including 
SMAD4. This complex then translocates into nucleus, binds with DNA, and 
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stimulates the expression of target genes (191, 192). As SMAD4 is a key mediator 
of TGFβ responses and can interact with all the R-SMADs, it is not surprising that 
SMAD4 alterations have been found in up to 16% of colon cancer (193). 
Pholnukulkit and coworkers (194) investigated the importance of SMAD4 in 
TGFβ signaling pathway. Their study suggested that deletion of SMAD4 leads to 
a defect of formation of SMAD2/SMAD4 complex upon activin A (TGFβ family 
member) stimulation in HT-29 colon cancer cell line. It was also shown by 
Schwarte-Waldhoff et al. that re-expression of SMAD4 in SW480 colon 
carcinoma cells could suppress the tumor formation in nude mice, which provides 
definite proof for its tumor suppressor (195). However, they further reported that 
expression of SMAD4 did not affect growth rates of SW480 cells in vitro. Since 
SW480 cells endogenously express high levels of TGFβ (196), their findings 
indicated that SMAD4 reconstitution initiated other pathways to impede 
tumorigenesis rather than restored a TGFβ induced growth inhibitory effect. 
TGFβ independent way of SMAD4 mediated tumor suppression may be involved 
in transcriptional regulation of E-cadherin (197), uPA and PAI-1 genes (85). 
These findings suggested a potential role for SMAD4 as a modulator of cell 
adhesion and invasion. 
 
3.3 Epigenetic alterations in colorectal cancer 
    Epigenetic changes are modifications of the genome heritable during cell 
division that do not involve a change in DNA sequence (198). Epigenetic 
dysregulation has been increasingly recognized as an important mechanism in 
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tumorigenesis since its discovery in human tumors in 1983 (199, 200). This 
dysregulation includes hypomethylation, which leads to oncogene activation and 
chromosomal instability, hypermethylation and tumor suppressor gene silencing, 
and chromatin modification acting directly and cooperatively with methylation to 
modify gene expression. In addition, disrupted genomic imprinting appears to 
contribute to colorectal cancer risk. 
 
3.3.1 DNA methylation  
        DNA methylation is present throughout the majority of the genome and is 
maintained in relatively stable patterns that are established during development 
(201). In humans, approximately 70% of CpG dinucleotides are methylated. 
However, there are regions that contain higher proportions of CpG dinucleotides 
called CGIs, which are 0.2-3 kb long sequences and are composed of greater than 
50% cytosines/guanines. They are present in the 5’ region of approximately 50%-
60% of genes and are normally maintained in an un-methylated state (202). In 
cancers, many of these CGIs become aberrantly methylated, and this aberrant 
methylation can lead to transcriptional repression.   
    Colon tumors exhibit hypermethylation of tumor suppressor genes (203). 
Previous studies indicate that DNA hypermethylation may occur not only 
secondary to a genetic predisposition in the colorectal carcinogenesis, but also are 
key pathogenic events in cancer formation that drive the initiation and progression 
of the ACF-adenoma-carcinoma sequence (204).   
   DNA hypomethylation is also found in both human and rat colon tumors. DNA 
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hypomethylation has been shown to increase chromosomal instability, to increase 
histone acetylation and to be associated with increased expression of growth-
related genes in carcinogenesis (205, 206).  
 
3.3.2 Epigenetic changes in Wnt pathway components  
    Transcriptional silencing of APC by promoter methylation has been suggested 
as an alternative to somatic mutation in colorectal tumorigenesis. Recently, the 
methylation of CpG sites in the promoter region of APC gene has been reported in 
different types of cancers, including colorectal cancer (207-209). Esteller et al. 
(208) analyzed the APC promoter methylation in human colorectal cancer. They 
reported that the APC promoter is hypermethylated in 18% of primary sporadic 
colorectal carcinomas (n=108) and adenoma (n=48), and neoplasia with APC 
methylation fails to express the APC transcript, suggesting that it is an early event 
in colorectal carcinogenesis. Deng et al. (210) has shown convincingly that 
methylation leads to reduction or loss of APC expression. In this study, they 
observed the methylation status of APC promoter in 22 colorectal cancer cell lines 
with different APC expression levels. They found that the methylation of CpG 
sites was invariably correlated with the loss of gene expression. By nuclease 
accessibility assay, they also observed a correlation between the closed chromatin 
conformation in APC promoter and loss of gene expression. When the low-
expressing or non-expressing cell lines were treated with a DNA 
methyltransferase inhibitor, 5-aza-2'-deoxycytidine (5-aza-dC), the APC 
expression in these cells was induced, CpG sites were demethylated, and closed 
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chromatin conformation was opened.  
    Several other studies have reported methylation of the promoters of other Wnt 
pathway members, including Dickkopf-1 (DKK1) (211), Wnt inhibitor factor-1 
(WIF1) (212) and secreted frizzled-related proteins (SFRPs) (213). These three 
family members are distinct classes of extracellular Wnt antagonists and may be 
expected to counter persistent tumorigenesis stimulated by Wnts. DKK-1 is a 
candidate gene for hypermethylation-associated transcriptional inactivation in 
human cancer since a 5'-CpG island is located around its transcription start site 
and it has been previously reported to be downregulated in human colon cancer 
(214). DKK-1 gene is transcriptionally silenced by CpG island promoter 
hypermethylation in colon cancer cell lines, whereas treatment with the DNA-
demethylating agent 5-aza-dC restored DKK-1 expression (211). Similar 
experiments have been performed in analyzing the association of methylation 
level and WIF-1 mRNA expression (213). An increased methylation of the 
promoter region was demonstrated in a cohort of 51 advanced colorectal cancers. 
Caldwell et al. (215) reported that hypermethylation was identified in 82% 
cancers and in only 30% matched normal mucosal samples (P < 0.001), 
comparable with the 95% found by Suzuki et al. Reduced transcript levels were 
also seen in >75% of these cases. The best evidence that methylation changes 
have functional consequences comes from study of the WIF-1 (216). 
Downregulation of WIF-1 expression was observed in 72.7% of 44 colorectal 
adenoma tissues and 78.2% of 23 early mucosal or submucosal colorectal 
carcinoma tissues. Furthermore, no significant association between WIF-1 
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downregulation and clinicopathological characteristics was found, suggesting that 
downregulation of WIF-1 expression is an early event in carcinogenesis of these 
cancers (216). Treatment with demethylating agent, 5-aza-dC, restored WIF-1 
expression in colon cancer cell lines. Transfection of the WIF-1 gene construct 
into SW48 colon cancer cell line lacking WIF-1 expression resulted in a 
significant inhibition on colony formation and cell proliferation.  
 
 
3.3.3 Epigenetic changes in other tumor suppressor genes  
 
    Inactivation of hMLH1 presumptively plays an initiating role in the 
pathogenesis of MSI colon cancers. Accumulating evidence suggest that aberrant 
methylation exists in the promoter of hMLH1 in sporadic MSI colon cancers, and 
the hMLH1 expression can be restored by demethylating the hMLH1 promoter in 
cell lines (217, 218). Structure analysis of the methylation status of specific CpGs 
in the hMLH1 promoter has shown that the methylation status of small clusters of 
CpGs in the 5’ region of the hMLH1 promoter appears to dictate the 
transcriptional status of the gene through interfering with CBF transcription factor 
binding to a CCAAT box (219), resulting in decreasing downstream genes 
expression. Moreover, the aberrant hypermethylation of 5’ CpG dinucleotides 
could silence a variety of tumor suppressor genes including CHD1 (E-cadherin), 
p16, etc. Grady et al. (220) demonstrated that loss of expression of CDH1 
concurrent with CpG methylation of the wild type CDH1 allele in tumors that 
occur in the setting of hereditary diffuse gastric cancer. However, more recent 
study questioned the role of CDH1 hypermethylation in colon cancer initiation. 
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Kim et al. (221) measured the methylation status of eight genes from adenomas to 
adenomacarcinomas, including CDH1. Unexpectedly, CDH1 methylation 
decreased with tumor progression (chi-square test for trend, p=0.023). Another 
tumor suppressor gene that has been studied is p16INK4a. Although mutation of 
p16INK4a has not been described in colon cancer, methylation of p16INK4a is 
detected in 18% (222) to 50 % (223) of colon cancer and 75% colon cancer cell 
lines (224), and has been found not only in colon cancer, but also in adenomas 
(225). This observation demonstrates that aberrant promoter methylation is 
occurring early in the adenoma sequence.  
 
3.3.4 Folate and colorectal carcinogenesis 
Folate and one-carbon metabolism 
    One-carbon metabolism is a network of interrelated biochemical reactions in 
which a one-carbon unit is transferred to tetrahydrofolate for subsequent reduction 
or oxidation (226). The transfer of this one-carbon moiety into biochemical 
pathways is essential for DNA synthesis and DNA methylation (Fig. 2). 5, 10-
methylenetetrahydrofolate, an intracellular form of folate, is required for 
conversion of deoxyuridylate to thymidylate and can be oxidized to 10-
formyltetrahydrofolate for purine synthesis. Thus, folate is an important cofactor 
for DNA synthesis. Folate also plays an essential role in one-carbon transfer 
involving remethylation of homocysteine to methionine, thereby ensuring the 
provision of S-adenosylmethionine (SAM), the primary methyl group donor for 
most biological methylation reactions (227). After transfer of the methyl group,  
 
Fig. 2. Simplified scheme of folate metabolism involving 
DNA synthesis and methylation (227) 
 
SAM is converted to S-adenosylhomocysteine (SAH) by DNA 
methyltransferases. Methyl group is then transferred to DNA sequence. 
Folate deficiency and colorectal carcinogenesis 
    Folate deficiency has been associated with colorectal cancer risk based on the 
biochemical function of folate in mediating one-carbon metabolism.  In 1992, 
Cravo (228) first proposed that folate deficiency enhances colorectal 
carcinogenesis because of evidence from animal experiments that demonstrated 
altered folate status could affect genomic DNA methylation. However, the effect 
of isolated folate deficiency on DNA methylation in the colorectum has not yet 
been clearly elucidated. In rodent studies, folate deficiency in conjunction with a 
colorectal carcinogen (dimethylhydrazine (DMH) or azoxymethane (AOM)) 
failed to induce significant genomic DNA hypomethylation in rat colon (229-
231). On the other hand, several studies reported that folate deficiency could 
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diminish the occurrence of colorectal cancer, which may be attributed to the 
known role of folate in cell multiplication (231, 232).  
    Accumulating evidence over the past decade suggests that folate status 
(assessed by dietary folate intake or by the measurement of blood folate levels) is 
inversely related to the risk of sporadic and ulcerative colitis-associated colorectal 
cancer (CRC) or its precursor, adenoma (233-235). In some human intervention 
studies, folate supplementation increased the extent of colonic genomic DNA 
methylation in subjects with colorectal adenoma or cancer (236, 237).  
In conclusion, the effect of folate deficiency on DNA methylation in the colon 
in animal studies are inconsistent and do not support the hypothesis that folate 
deficiency induces DNA hypomethylation in the colon, whereas folate 
supplementation appears to be capable of increasing the degree of DNA 
methylation in the colorectum in some human studies. Therefore, the potential for 
folate to modulate DNA methylation and thus modify colorectal cancer risk still 










4. Models of colorectal cancer 
    Animal models have contributed significantly to understanding of the 
carcinogenesis and the environmental factors involved in the pathogenesis of 
colon cancer (238). The ideal animal model should mimic the human disease in 
terms of morphology, biochemical alterations, and biological behavior (239). 
Unfortunately, although each animal model can approximate part of the 
characteristics of human CRCs, they all have limitations. A meta-analysis showed 
that the effects of aspirin, β-carotene, calcium, and wheat bran were not strikingly 
different in humans and animal models. However, some chemopreventive agents 
cannot produce the same effect in animals and in humans (240).  The advantages 
and limitations of these animal models are addressed below.  
 
4.1 Models of chemically induced colorectal cancer 
    Carcinogens can induce colorectal cancer in rats and mice. Frequently used 
carcinogens are dimethylhydrazine (DMH) and its metabolite azoxymethane 
(AOM), N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and N-methyl-N-nitroso-
urea (MNU) (241). Carcinogens can be administrated via four routes: oral, 
subcutaneous, intrarectal and intramuscular. The incidence of CRC development 
depends on the carcinogen used, the dosage, the duration and frequency of 
administration, and the routing and timing of administration. Kobaek-Larsen et al. 
(242) states that intrarectal administration of DMH or AOM or MUN in rats is 
much more effective than oral dosing in the development of colorectal cancer. 
Additionally, the sex, age and genetic background of the mice can affect the 
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incidence of CRC development. Moreover, the effective concentration of these 
carcinogens can be influenced by the intestinal flora, the diet and the 
immunological status of the animals (241).  
    Many investigators use AOM to induce colon tumors and to study the effects of 
nutritional factors and chemopreventive agents. AOM has been demonstrated to 
be a potent inducer of carcinomas of the large intestine in various strains of male 
and female rats. Endoscopic examination of animals treated with AOM revealed 
that the first visible colon tumors can be detected 15 weeks after treatment, and 
that the mean latency period of such tumors is about 20 weeks (242). AOM-
induced tumors share many histopathologic characteristics with human tumors, 
and follow the ACF-adenoma-carcinoma sequence. One of the characteristics of 
the human disease process reflected in the AOM-rat model is the occurrence of 
both adenomas and adenocarcinomas. Reddy’s study (238) indicated that in 
AOM-rat model, about 70% of colon tumors are adenocarcinomas, and the rest 
are adenomas. Like human colon tumors, enhanced cyclooxygenase-2 expression 
was observed in AOM-induced colon tumors (243). AOM treatment also induces 
K-ras mutation (30–60%) and β-catenin mutation (244-246), but, unlike human 
tumors, they seldom have Apc mutations (<15%) (240, 245), and never exhibit 
p53 mutations. 
 
4.2 Models of genetically mutant induced colorectal cancer 
    Mice homozygously deleted for Mlh-1 or Msh-2 develop lymphomas but are 
also prone to intestinal neoplasia and therefore represent a good model for 
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studying HNPCC development. Mlh1-/- mice 6 months or older develop 
gastrointestinal tumors in 33% of cases. Moreover, addition of an Apc gene 
mutation into the Mlh1-/- mice resulted in 100% GI tumor formation (247). These 
model reveal that exposure of MMR-deficient cells to endogenous mutagens may 
develop HNPCC.  
    Mice exhibiting Apc gene mutations have been used to study the general 
principles of carcinogenesis. The multiple intestinal neoplasia (Min) mouse, 
which carries a fully dominant mutation converting codon 850 of the murine Apc 
gene from a leucine to a stop codon, resulting in premature truncation of the Apc 
protein, was first reported by Moser et al. (248). This is similar to germline 
mutations in the APC gene in humans with FAP and sporadic cancers. On the 
C57BL/6J (B6) background, Min mice develop more than 50 adenomas 
throughout the intestinal tract and rarely survive beyond 120 days (248). Min 
mice also develop a variety of lesions in other tissues including desmoid tumors, 
epidermoid cysts and mammary tumors. This reflects part of the spectrum of 
lesions seen in humans with mutations in the APC gene (249). However, ACF and 
adenocarcinomas are not or seldom observed in this model. Consequently, the 
ACF to carcinoma progression is not established in this model (240, 245). 
Moreover, K-ras and p53 mutations are not detected in Min mice polyps, in 
contrast with human tumors (250), and p53 inactivation does not increase tumor 
number in Min mice (251). In addition, similar to humans, methylation plays a 
role in Min mice carcinogenesis, since a reduction in DNA methyltransferase 
activity suppresses polyp formation (15). After the Min mice discovery, other 
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mice have also been genetically modified on Apc with truncations in positions 
580, 716, 1309, or 1638 (245). Different mutations lead to different phenotypes, 
similar to the human condition. The average polyp number in Min mice is 40±20, 
which is six times fewer than Apc716 mutant mice. Apc 1309 and 1638 mice 
have 30 and 3 polyps respectively (245).  
Although Apc mutant mice are promising models for human CRC, the major 
drawback is that tumors occur predominantly in the small intestine and a few in 
the colon. In constrast, human tumors frequently exist in the colon. This 
discrepancy may be explained as a result of differences in key enzymes between 
the small and large bowel of Min mice. For instance, phospholipase A2 and 
cyclooxygenase-2 (COX-2) are upregulated in the colonic tumors of human and 
rat (253), but also in small intestinal tumors of Min mice (254, 255). The resulting 
increase in prostaglandin E2 (PGE2) level would promote cancer growth. 
Therefore, Min mice have more polyps in the small intestine. Another explanation 
is polyamine levels are lower in the colon than in the small intestine of Min mice 
(256, 257). The colorectal mucosa of individuals with FAP contains elevated 
levels of the proliferation-associated polyamines. In Min mice, mRNA content of 
ornithine decarboxylase (ODC), the first enzyme in polyamine synthesis, is 
increased in both the small intestine and colon; while mRNA content of antizyme 
(AZ), a protein which negatively regulates ODC, is decreased significantly in the 
small intestine but not the colon (257).  Consistent with the changes in ODC and 
AZ gene expression, small intestinal, but not colonic, polyamine content was 
elevated in Min mice compared with normal littermates. Treatment of the Min 
 52
mice with ODC inhibitor, difluoromethylornithine (DFMO), decreased small 
intestinal, but not colonic tumor number. Therefore, this low level of polyamines 






















5. Obesity and colorectal cancer 
5.1 Yellow obese mouse model 
    The agouti gene has been mapped and identified in a number of species (258, 
259). Cloning and sequence analysis revealed that the mouse agouti gene is 
located in the distal region of chromosome 2 and encodes for a small-secreted 
protein. In wild-type mice, agouti is only expressed in the skin during the hair 
growth cycle (260). The human homologue of agouti is located on chromosome 
20 and encodes a 132 amino acid protein, agouti signal protein (ASIP) (261). 
Despite the high degree of protein homology (85% of amino acids identical to 
mouse) the expression pattern is different. Whereas mouse agouti is only 
transiently expressed in the hair follicles, human agouti is expressed in diverse 
tissues; primarily adipose tissue followed by testis, heart, ovary and at low levels 
in liver, kidney and foreskin (261, 262).  
    The mechanism of agouti action on coat color is based upon antagonism of 
melanocorin receptors, resulting in a shift from eumelanin to phaeomelanin 
synthesis within the hair follicle. α-melanocyte stimulating hormone (α-MSH) 
binds to its receptor, melanocortin 1 receptor (MC1-R), which is coupled to the 
heterotrimeric guanine nucleotide binding proteins that activate adenlyate cyclase. 
The resulting increase in intracellular cAMP levels leads to the activation of the 
rate limiting enzyme in melanogenesis, tyrosinase. Agouti antagonizes the 
binding of α-MSH to MC1-R, thereby decreasing the overall rate of 
melanogenesis and increases the incorporation of sulfhydryl compounds into 
dopaquinone to produce yellow pigment (263-266).  
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    Two of the dominant agouti mutations have been studied extensively, namely, 
“lethal yellow” (Ay), first described by Cuenot (260), and “viable yellow” (Avy), 
first described by Dickie (266). The lethal yellow mutation is characterized by 
prenatal lethality of the homozygous Ay/Ay genotype. The viable yellow Avy/- 
phenotype differs from that of the clear yellow Avy/- phenotype by exhibiting 
eumelanic mottling, i.e., irregular areas or small spots of agouti/black hair on a 
yellow background (267). Molecular definition of these mutations was first 
identified at the Oak Ridge National Laboratories (260). Briefly, Ay is 
characterized by a 120-170kb deletion that includes the entire coding regions of 
the Raly (heterogeneous nuclear ribonucleo-protein associated with lethal yellow) 
gene as well as the non-coding exon of agouti. As a result, the Ay allele is under 
the control of the Raly promoter, which is normally constitutively expressed in all 
somatic cells (268). Therefore, the Raly promoter overrides the agouti gene’s 
promoter in regulating its transcription and thus induces formation of yellow 
pigment by the hair follicle melanocytes. The embryonic lethality, which is 
associated with the Ay/Ay genotype, may actually result from the absence of Raly 
expression in the developing embryo (267). The ubiquitous over-expression of the 
agouti gene is also the basis to the syndrome expressed by Avy/-mice. It is due to 
insertion of an intracisternal A particle (IAP) into noncoding exon 1A (269).  
    Transgenic mice ubiquitously over-expressing agouti become obese, develop 
diabetes and tumors (270). Agouti expression in skin has little effect on the 
obesity phenotype. It is likely that Mc4r and Mc3r are responding to ectopic 
agouti protein expression, resulting in weight gain. Mc4r is expressed in the 
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hypothalamus and plays a role in the regulation of feeding and metabolism (271). 
Administration of a Mc4r agonist inhibits feeding and administration of a Mc4r 
antagonist increases feeding suggesting that agouti protein, an antagonist of Mc4r 
may play a role in agouti-induced obesity (272). Mouse agouti protein also 
antagonizes Mc3r. Mc3r knock-out mice have increased fat mass, reduced lean 
mass and a greater feeding efficiency compared with wild-type mice (273). 
Ectopic expression of agouti protein in adipocytes may lead to an inhibition of 
lipolysis and stimulation of lipogenesis. Data from Moustaid and colleagues (274) 
suggest that lethal yellow mice have increased levels of fatty acid synthetase 
(FAS) and stearoyl-CoA desaturase (SCD), which are involved in fatty acid 
synthesis and desaturation of saturated fatty acids, relative to lean controls. 
Treatment of   3T3-L1 adipocytes with recombinant agouti protein increased FAS 
and SCD mRNA levels 1.5 and 4 fold, respectively (274). Adrenocorticotropic 
hormone (ACTH) is a potent lipolytic hormone. In mouse adipocytes (275), 
ACTH can bind to Mc2r and elevate cAMP, resulting in stimulating lipolysis 
(275). Therefore, agouti protein antagonism of ACTH to adipocytes may lead to 
an inhibition of lipolysis.  More recently, agouti has been shown to up-regulate 
adipocyte transcription factors, signal transductors and activators of transcription 
(STAT1 and STAT3) and peroxisome proliferators activated receptor (PPAR)-γ 
protein in 3T3-L1 adipocytes and in transgenic mice expressing agouti in adipose 
tissue (272, 276).  
    The divergence of in expression patterns between mice and humans suggests 
that agouti may have functions other than pigmentation in humans. The link 
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between agouti expression in human adipose tissue and obesity/type2 diabetes 
was investigated. Voisey’s study (277) indicated that agouti mRNA was 
negatively correlated with BMI in men but not in women. Smith and coworkers 
(278) did experiments with cultured human pre-adipocytes and cells obtained 
from transgenic mice. They found that over-expressing agouti could regulate both 
pre-adipocyte proliferation and differentiation through melanocortin receptor 
(MCR) signaling in adipose tissue, which demonstrated that agouti/melanocortin 
system is a potent regulator of adipogenesis in humans.  
      
5.2 Summary of epidemiologic evidence of obesity and CRC 
    The relationship between excess body weight and the incidence of colon cancer 
has been well established in epidemiological studies (279-283). In 1992, Lee and 
Paffenbarger (282) reported that obesity in adolescence was found to be strongly 
related to colonic cancer. Similar relationships are also seen for colon adenoma, 
with stronger associations for larger adenomas (283). Four years ago, the 
International Agency for Research on Cancer (IARC) published a comprehensive 
evaluation of the available literature on weight and cancer. Their report concluded 
that obesity had been consistently associated with higher risk of colorectal cancer 
in men (relative risks of approximately 1.5-2.0) and women (relative risks of 
proximately 1.2-1.5) in both case-control and cohort studies (284). However, 
there is a different association of body weight with colon cancer risk between men 
and women. The BMI has been found to be positively related to the risk of colon 
cancer in men (284), whereas this association is less consistent and weaker for 
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women (285-287). One reason for the discrepancy is that men and women have 
the different body compositions. Support for this, two recent cohort studies found 
that waist circumference and waist-to-hip ratio (WHR), indicators of abdominal 
obesity, were strongly associated with colon cancer risk in both men and women 
(288, 289), which indicate that abdominal obesity is a risk factor for colon cancer 
in both sexes. Another explanation for sex difference may be related to the 
differences and changes in estrogen levels in women. The modifying effect of 
estrogen suggests that estrogen may enhance the association between BMI and 
colorectal cancer (290). Hormone Replacement Therapy (HRT) use has been 
associated with reduced risk of colon cancer (291, 292). A meta-analysis of 18 
observational studies of colorectal cancer and HRT also indicated a 20% 
reduction in colon cancer among ever users compared with never users (RR=0.80) 
and a 34% reduction among current users (RR=0.66) (293).  
 
5.3 Current hypothesis for correlation between obesity and CRC 
    Adipose tissue is an active endocrine and metabolic organ that can have effects 
on the energy balance and lipid metabolism of other tissues. It also regulates their 
physiology through the release of hormones such as leptin, adiponectin, resistin 
and tumor necrosis factor-α (TNF-α).  
 
5.3.1 Chronic hyperinsulinaemia  
    Recently, Giovannucci (294) outlined a mechanism by which elevated BMI 
may influence colon cancer risk and suggested that altered glucose-insulin 
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dynamics may be involved. Excess weight results in increased release of free fatty 
acids, resistin and TNF-α and reduced release of adiponectin by adipose tissue, 
which develops insulin resistance, a metabolic state characterized by reduced 
insulin sensitivity in liver, skeleton muscle and other tissues. Chronically 
increased insulin may exert a tumorigenic effect which is mediated by binding to 
insulin receptors in the neoplastic cell surface or by the changes from 
hyperinsulinaemia. Secondary to hyperinsulinaemia, insulin promotes the 
synthesis and biological activity of insulin-like growth factor 1 (IGF-1) that 
regulates cellular proliferation. In addition, insulin has effects on the synthesis 
and biological activity of sex hormones (estrogen, androgens and progesterone) 
that also play a role in the association between obesity and CRC, as discussed in a 
subsequent section (5.3.2 IGF-1 and IGFBP). 
     In vitro studies demonstrated that insulin stimulates growth of normal colonic 
and carcinoma cells (295-297). Similarly, cancer-enhancing effect of insulin has 
been demonstrated in animal models in which either animals are treated with 
insulin injections (298) or fed a high energy, high fat diet that lead to insulin 
resistance (299).  
    Epidemiological evidence that insulin is associated with colorectal cancer 
(CRC) risk is showing a relationship between type 2 diabetes and especially 
visceral obesity and CRC. The major environmental determinants of type2 
diabetes include high body mass index (BMI), increased central obesity, physical 
inactivity, and excessive intake of energy and dietary patterns that stimulate 
secretion of insulin. These factors are remarkably similar to the constellation of 
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risk factors emerging for colon cancer. In one large prospective study of women 
(300), diabetic women had a 43% increased risk of colorectal cancer and a 49% 
increase in colon cancer compared with non-diabetic women. Another recent 
study found that women with a type 2 diabetes history were at increased risk of 
colorectal cancer (RR=1.55, 95%CI=1.04-2.31) (301).  
     
5.3.2 IGF-1 and IGFBP 
    The principle stimulus for the synthesis of IGF-1 is in the liver, which is the 
source of over 80% of circulating IGF-1. Because more than 90% of IGF-1 is 
bound to IGFBP-3, little IGF-1 is circulating free. The synthesis and biological 
activity of IGF-1 is regulated by insulin. High levels of insulin in type2 diabetics 
cause an increase in hepatic growth hormone (GH)-receptor level, resulting in 
increases GH activity and increased synthesis and blood levels of IGF-1 (302). In 
addition, insulin reduces hepatic secretion of IGFBPs and inhibits IGF-1 action in 
vitro (303).  
    Epidemiological studies suggest that increased serum levels of IGF-1 and 
decreased levels of IGFBP-3 may be independently related to risk of colorectal 
cancer (304-306), suggesting that it is the ratio of IGF-1/IGFBP-3 that is relevant 
in relation to colorectal cancer risk. For example, in the Nurses’ Health Study, 
three stages of colorectal carcinogenesis were examined in relation to base-line 
plasma IGF-1 and IGFBP-3 (305). Controlling for IGFBP-3 level relative to 
women in the low tertile of IGF-1, those in the high tertile were at elevated risk of 
colorectal cancer (RR=2.18; 95% CI, 0.94-5.08) and high-risk adenoma 
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(RR=2.78; 95% CI, 0.76-9.76). Controlling for IGF-1 level, women in the high 
tertile of IGFBP-3 were at lower risk of colorectal cancer (RR=0.28; 95% CI, 
0.10-0.83) and high-risk adenoma (RR 0.28; 95% CI, 0.09-0.85). Neither IGF-1 
nor IGFBP-3 had any appreciable relation to small, tubular adenomas. A very 
recent study concerning IGF-1, IGFBP-3 and adenoma risk indicated that ratio of 
IGF-1/IGFBP-3 and levels of IGF-1 are associated with adenomatous polyps in 
comparison with non-adenoma controls (307). However, a meta-analysis of IGF-1 
and IGFBP-3 and colorectal cancer showed only a modest association with IGF-1 
and no protection with IGFBP-3, and regression models could not confirm a dose-
response association of IGF-1 and colorectal cancer (308). In a cohort of 14,275 
women in New York, baseline IGF-1 and IGFBP were assayed from the serum of 
102 women who subsequently developed colorectal cancer and 200 matched 
control subjects (309). Colorectal cancer showed a modest but positively 
increased risk with higher levels of IGF-1 but also an increased risk with higher 
levels of IGFBP-3. Thus, the association of IGF-1 with CRC has not been 
consistently observed.  
    The biologic basis for the role of IGF-1 in CRC pathogenesis is based upon 
IGF-1 regulation of cell proliferation, differentiation, metastasis and apoptosis 
(310, 311). The action of IGF-1 is initiated by binding to IGF-1 receptors. Both 
colorectal epithelia normal and cancer cells express IGF-1 receptors in vitro; 
when activated by IGF-1, the receptor-ligand complex inhibits apoptosis and 
allows progression through the cell cycle (312). Support for this is provided by 
Lahm’s study (313), which indicated that stimulation by IGF-1 cause’s 
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proliferation in vitro while blocking IGF-1 receptor inhibits growth of colorectal 
cancer cells. Further support for a link between the IGF-1 and cancer is that over-
expression of IGF-1 receptors is critical for the survival of transformed cells 
(314). In addition, IGFBP-3, which can oppose those of IGF-1 in part by binding 
IGF-1 and thus reducing free IGF-1 levels, may act as an independent apoptotic 
agent (315, 316) and inhibit target cells. In tissues, IGFBP proteases can enhance 
IGF-1 availability by cleaving IGFBP, thereby increasing free IGF-1 
concentration. Therefore, the biological activity of IGF is determined by the 
integrated actions of circulating IGF-1 and IGFBP and by local production of 
IGF, IGFBP and IGFBP proteases (316).   
 
5.3.3 Estrogen 
    Clinical studies also indicate that the incidence of colon cancer is lower in 
women than in men (317), suggesting a role for estrogen in colon tumorigenesis. 
Estrogen acts by binding to the estrogen receptor (ER), a ligand-activated 
transcription factor that regulates transcription of target genes in the nucleus by 
binding to estrogen response element (ERE) regulatory sequences in target genes 
and recruiting co-regulatory proteins (CoRegs) such as coactivators (318).  ER-β 
is the predominant ER form in both normal and malignant human colon tissue, as 
well as human colon cancer derived cell lines (319, 320). ER-β protein levels are 
reportedly lower in colon tumors compared with normal colon tissue, and loss of 
ER-β is associated with advanced stages of colon cancer and tumor cell 
dedifferentiation, suggesting a protective role for ER-β in colon tumorigenesis 
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(320, 321). 
    Adiposity influences the synthesis and bioavailability of endogenous estrogens 
(322). Adipose tissue expresses various sex-steroid-metabolizing enzymes that 
promote the formation of estrogens from androgenic precursors. In men and 
postmenopausal women, adipose tissue is the main site of estrogen synthesis, and 
BMI is directly related to circulating levels of estrone and estradiol (323). 
 
5.3.4 Adipokines and CRC 
    Epidemiological studies have identified obesity as one of the major risk factors 
for cancer. A recent prospective study over a period of 16 years on 900,000 adults 
in the United States by Calle et al. (324) showed an association between increased 
BMI and risk of death from all cancers. The cross talk between cancer cells and 
adipose tissue has been increasingly accepted (325). The contributions may be 
due to the adipocyte-derived factors.  
 
Leptin and CRC 
    Leptin is a highly conserved 16-kDa hormone and it is predominately 
expressed in adipose tissue. Leptin appears to play a role in regulating energy 
homeostasis, neuroendocrine and immune function (325, 326). A relationship 
between leptin signals and the pathogenesis of colon cancer was suggested in both 
mice and human studies. db/db mice have obese and diabetic phenotypes due to 
disruption of the leptin receptor. Recent studies using this genetic mouse model 
treated with azoxymethane, a powerful carcinogen that causes chemically induced 
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colon cancer, found that increased azoxymethane-induced pre-malignant colon 
lesions were detected in homozygous db/db mice compared to heterozygous or 
wild strains (327). The case-control studies showed that leptin is elevated in obese 
individuals (328, 329). In Statin’s study (329), serum leptin levels were measured 
from men diagnosed with cancer of the colon or rectum after blood collection, and 
the controls matched with age and date of blood collection. The data showed an 
approximately 3-fold increase in colon cancer risk with increasing concentrations 
of leptin up to an odds ratio (OR) of 2.72 for top vs. bottom quartile. Moreover, 
energy restriction, a well-established protective factor against cancer, decreases 
leptin levels (330). However, one animal study did not support the role for leptin 
in carcinogenesis promotion (331); leptin administration to azoxymethane-
induced Fischer 344 rats significantly inhibited ACF formation in the middle and 
distal colon compared with controls (p=0.006). That study provides the first 
evidence that leptin reduces the development of chemically induced precancerous 
lesions in colon. In vitro, leptin stimulated proliferation and invasiveness of 
human colon cancer cells (332-334). Leptin has also been demonstrated to 
stimulate angiogenesis, which is essential for tumor growth, invasion and 
metastasis (335).  
    Leptin acts by binding to its receptor. The presence of leptin receptor (Ob-R) 
has been demonstrated in normal, precancerous and malignant human colonic 
epithelium as well as in colon cancer cell lines. Activation of the leptin receptor 
has been reported to activate multiple signaling pathways in different system, but 
the mechanisms involved in the regulation of colonic epithelial function remain to 
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be determined. One study (336) indicated that the proliferative and anti-apoptotic 
actions of leptin in human colon cancer cells involved activation of JNK mitogen 
activated protein kinase (MAPK), JAK2 and PI3 kinase/Akt. Fenton (334) 
reported that leptin induced elevated IL-6 production in preneoplastic ApcMin/+ 
IMCE cells, and it was associated with STAT3, ERK, p38, MEK and JAK2 
activation and associated STAT3 nuclear activation and translocation.  
 
Adiponectin and CRC 
    Adiponectin is also called 30-kDa adipocyte complement-related protein, 
Acrp30, adipoQ, APM-1 and gelatin-binding-protein-29 and is the most abundant 
cytokine produced by adipocytes (337), with circulating levels approximately two 
to three times higher in females than in males (338, 339). Human adiponectin is a 
274-amino acid and 30-kDa protein hormone and encoded by the gene APM1 
located on chromosome 3q27 (340). Adiponectin consists of three domains 
including an N-terminal signal peptide, a collagen–like motif and a C-terminal 
C1q-like globular domain. At least two forms, that is low molecular weight 
(LMW) oligomers that is hexamers (two trimers) and high molecular weight 
(HMW) oligomers consisting of four-six trimers, exist in serum (341, 342). It has 
been suggested that the HMW adiponectin complex is the major source of the 
active form of this protein (342). Adiponectin is abundant in human plasma, with 
concentrations ranging from 3 to 30 μgml-1 and accounting for up to 0.05% of 
total plasma protein (343).  
    Adiponectin acts as an insulin-sensitizing hormone (344, 345) but also has anti-
 65
inflammatory (346) and anti-atherogenic effects (347, 348). Unlike leptin and 
TNF-α, circulating adiponectin levels are decreased with increasing adiposity 
(349, 350). Low levels of adiponectin may thus provide a link between obesity 
and risk of colorectal cancer. This hypothesis has been evaluated in several 
epidemiological studies. Otake et al. performed a case-control study to examine 
visceral fat accumulation and the levels of adiponectin in Japanese patients with 
colorectal adenoma. They reported that the patients with colorectal adenoma 
showed significantly more visceral fat and significantly less plasma adiponectin 
concentration in comparison with the controls (adds ratio (OR)=2.19, 95% 
confidence interval (95% CI)=1.47-3.28; p<0.001 and OR=0.24, 95% CI=0.14-
0.41; p<0.001, respectively) (351). Wei and coworkers conducted another study to 
evaluate the association between plasma adiponectin and risk of colorectal cancer 
among 18,225 men in the Health Professional Follow-up Study. In this ongoing 
prospective cohort study, they observed a statistically significant inverse 
association between plasma levels and risk of colon cancer (352). However, one 
observational case-control study contradicts the epidemiological data linking 
adiponectin to colon carcinogenesis (353). In that study, serum adiponectin levels 
were determined from 381 colorectal cancer cases and 381 controls. The results 
showed that there was no association between adiponectin level and risk of 
colorectal, colon, or rectal cancer in the whole study population. More recently, a 
proinflammatory role of adiponectin was suggested in chemically induced colitis 
by demonstration that adiponectin induced production of proinflammatory 
cytokines and inhibed bioactivity of protective growth factors (354). Furthermore, 
 66
in the human colonic epithelial cell line HT-29, adiponectin stimulated 
proliferation and production of proinflammatory cytokines, with a potentially 
distinct role of the globular fragment compared with full-length adiponectin 
(355).  
    The potential inhibitory role of adiponectin on tumorigenesis is also suggested 
by the demonstration that adiponectin was inversely correlated with fasting 
plasma insulin (356). Several studies have supported the association of elevated 
insulin production and decreasing levels of IGFBP-1 and IGFBP-3, with an 
increased risk of developing colorectal malignancies (357, 358). Therefore, low 
adiponectin levels can potentially lead to carcinogenesis through altered effect of 
insulin on tumor cell proliferation. Another mechanism linking adiponectin with 
reduced tumorigenesis is through signaling pathways. Several signaling molecules 
such as 5’-AMP-activated protein kinase (AMPK), nuclear factor κB (NF-κB), 
PPAR-α and p38 MAPK are known to mediate adiponectin-induced metabolic 
effects (358). More recently, JNK and STAT3 were also shown to be downstream 
effectors of adiponectin (359). Through these signaling pathways, adiponectin 
might reduce the risk for developing colorectal cancers. Finally, adiponectin may 
also inversely regulate angiogenesis through induction of apoptosis in vascular 
endothelial cells by activating the caspase cascade (360).   
 
Interleukin (IL)-6 and CRC 
    Inflammation has been linked to risk of colorectal cancer (361). Excess 
adiposity is linked to higher serum concentrations of inflammatory markers, IL-6, 
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TNF-α and C-reactive protein (CRP) (362).  
    IL-6 is mainly produced by visceral fat (363) and the elevated IL-6 production 
induced by leptin promotes cell proliferation in an Apc (Min/+) colon epithelial 
cell line (364). In vivo, IL-6 binds to its soluble receptors (sIL-6R, sIL-11R, 
soluble ciliary neurotrophic factor receptor) and stimulates several types of target 
cells which could not been stimulated by IL-6 alone. This process has been named 
trans-signaling. Jones et al have shown that in several chronic inflammatory 
diseases, including colon cancer, trans-signaling via the sIL-6R complexed to IL-
6 is a crucial point in the maintenance of the disease, by promoting transition 
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1.1 Abstract 
Although high calcium diets have been reported to reduce the risk of colorectal 
cancer, our preliminary data with the ApcMin/+ mouse shows a paradoxical 
increase in intestinal tumor loads (>65%) with high calcium diets. Since we 
previously demonstrated that increasing dietary calcium reduces adiposity, and 
ApcMin/+ mice on high calcium diets exhibited profound loss of adipose tissue, we 
hypothesized that loss of an adipose tissue-derived tumor suppressor factor(s) 
resulted in increased tumor susceptibility in animals on the high calcium diet. 
Accordingly, tumor prone ApcMin/+ mice were crossed with obesity prone Ay/a 
mice to generate obese Ay/ApcMin/+ mice. Low (0.2%), normal (0.5%), and high 
(1.2%) calcium diets were fed to both Ay/ApcMin/+ mice and ApcMin/+ mice from 
35-40 days until 90 days of age (n=21/strain, n=7/ diet group). The high calcium 
diet reduced weight gain in both strains (p < 0.01) and reduced fat pad mass by 
46%-57% in Ay/ApcMin/+ (p < 0.004) and by 65%-82% in ApcMin/+ (p < 0.03). 
ApcMin/+ mice on the high calcium diet exhibited an increase in tumor number (76 
vs. 29, p = 0.009), but this effect was not seen in the Ay/ApcMin/+ mice. β-catenin 
and cyclin D1 gene expression were significantly induced with high calcium diet 
in intestinal tumor tissue of ApcMin/+ mice but not in Ay/ApcMin/+ mice. We 
conclude that the differential effect of dietary calcium on intestinal tumorigenesis 
in lean vs. obese ApcMin/+ may result from the loss of adipose-derived protective 
factor(s) due to the substantial loss of body fat in ApcMin/+ mice fed a high calcium 




    Epidemiological studies and clinical trials have reported an inverse association 
between dietary calcium intake and the incidence of colorectal cancer. As early as 
1985, Lipkin and Newmark published data indicating that dietary calcium was 
inversely associated with epithelial proliferation (1). Recent analysis of dietary 
patterns strongly suggests that high consumption of dairy products and fruits and 
vegetables may be associated with a decreased risk of colorectal adenomas (2). 
Clinical trials further indicate that supplementary calcium significantly reduces 
adenoma recurrence (3) and the risk for all types of colorectal polyps (4). Studies 
in rodents also have shown that a high calcium intake causes a reduction of 
epithelial cell proliferation in the colon and increases apoptosis in the distal 
colonic epithelium (5). However, some epidemiologic studies have yielded 
conflicting findings (6, 7).    
    The C57BL/6J-ApcMin mouse is highly susceptible to spontaneous intestinal 
adenoma formation due to a heterozygous, dominant mutation in the Apc 
(adenomatous polyposis coli) gene. The normal APC gene functions as a tumor 
suppressor and is involved in the up-regulation of genes implicated in normal 
differentiation and down-regulation of β-catenin transcriptional activity and 
transcriptional targets such as cyclin D1 (8). Loss of APC function with germ-line 
and/or spontaneous mutations of the APC gene initiates tumorigenesis in familial 
adenomatous polyposis and sporadic colorectal cancer (9, 10). The ApcMin/+ 
mouse model mimics the rapid development of adenomatous polyps that occur in 
humans with APC gene mutations, although tumors in this model occur 
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predominantly in the small intestine (11). Previous studies showed that colonic 
epithelial cell proliferation of Apc1638 mice (similar to ApcMin/+ tumor model) 
was significantly increased after consumption of a diet very low in calcium and 
vitamin D, and that normalizing dietary calcium and vitamin D could prevent 
these changes (12). However, Harris and coworkers (13) did not find an effect of 
a high calcium diet on polyp number or tumor load over the entire intestine in 
female ApcMin/+ mice. In contrast, our preliminary observations suggested that 
dairy calcium intake paradoxically promoted intestinal tumor growth in ApcMin/+ 
mice, and that this effect was accompanied by a profound loss of adipose tissue. 
Since we have previously demonstrated that increasing dietary calcium effectively 
reduces adiposity (14, 15), we hypothesized that this excessive loss of adipose 
tissue resulted in increased tumor susceptibility in ApcMin/+ mice on the high 
calcium dairy diet. 
    Agouti mutations result in ectopic expression of the agouti protein in mice. 
Lethal yellow (Ay) mutation is one of the dominant agouti mutations. It is 
characterized by embryonic lethality of the homozygous Ay/Ay genotype (16). The 
Ay genotype results from a large deletion that includes the coding regions of the 
Raly (heterogeneous nuclear ribonucleo-protein associated with lethal yellow) 
gene. Consequently, the Ay allele is under the control of the raly promoter, and 
ectopic overexpression of the agouti protein produces the effects, including 
yellow coat color, obesity, diabetes and tumor susceptibility (16, 17).  
    The current study was undertaken to examine the intestinal tumor load, in 
tumor-prone mice with varying degrees of adiposity provided diets containing 
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various levels of calcium. We report that the loss of marginal adipose stores in 
TApcMin/+ mice fed the high calcium dairy diet was associated with elevated tumor 
load, while this was not the case in Ay/ApcMin/+ mice with greater remaining 
adipose tissue. Our results provide evidence that there is a critical level of adipose 
tissue required to maintain a protective effect against intestinal tumorigenesis. 
 
1.3 Materials and methods 
Mice breeding and genotyping 
    The experiment was approved by the University of Tennessee Institutional 
Animal Care and Use Committee. To produce obese tumor-prone mice, we bred 
male C57BL/6J- ApcMin/+ (Jackson Laboratory, Bar Harbor, ME) at 6-7 weeks of 
age and female C57BL/6J- Ay mice to generate Ay/ApcMin/+ mice; our preliminary 
data demonstrated that this cross had no effect on the intestinal tumor load. Mice 
were genotyped for the Min mutation using DNA obtained by the HotSHOT (Hot 
sodium Hydroxide and Tris) extraction protocol (18) and a protocol provided by 
the Jackson Laboratory (19), and by coat color, for agouti. 
 
Experimental Design 
     Ay/ApcMin/+ and ApcMin/+ mice (n=21/strain) were generated from our breeding 
colony and genotyped as described above.  Mice (by strain) were randomly 
divided into 3 dietary groups (7 animals per group) with three levels of calcium 
(0.2%, 0.5% or 1.2% w/w) either in the form of carbonate calcium (0.2% and 
0.5%) or non-fat dried milk (1.2%, high calcium dairy diet).  Protein content in all 
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diets was adjusted to 14 energy %.  The mid-range (normal or standard) diet was 
based on content in the AIN-93G diet (i.e. 0.5% calcium diet). Each dietary group 
consisted of 4-5 males and 2-3 females.  During the experiment, the mice were 
housed individually and had free access to food and water. Food intake was 
measured daily and animals were weighed twice per week.   
    At 90 days of age, all mice were anesthetized with intraperitoneal injections of 
sodium pentibarbitol (50 mg/kg body weight).  Plasma samples were collected via 
cardiac puncture and kept at -20 °C. To determine the number and size of 
intestinal tumors, the entire intestinal tract was removed, flushed with ice cold 
phosphate-buffered saline (PBS) and opened longitudinally as described 
previously (20).  Tumor number and size were determined using a dissecting 
microscope (18X) (20). Four fat depots (abdominal, subcutaneous, epididymal 
and perirenal), and skeletal muscle (soleus and gastrocnemius) mass were 
weighted and immediately frozen at -80°C, with pooled samples of small 
intestinal tumors from individual mice.  
 
Plasma leptin and insulin radioimmunoassays  
    Leptin and insulin plasma concentrations were measured using 
radioimmunoassay kits for mouse leptin and rat insulin, respectively (Linco 





Total RNA extraction and quantitative real-time PCR 
    Total RNA from mouse intestine tissue was extracted by using a total cellular 
RNA isolation Kit (Ambion, Inc, Austin, TX) according to the manufacture’s 
instruction. Mouse  Bax gene, Bcl-2 gene, β-catenin gene and cyclin D1 gene 
expression levels of tumor intestine tissues were measured quantitatively using 
7300 Real Time PCR system (Applied Biosystems, Foster City, CA) with One-
step RT-PCR Master Mix (Applied Biosystems, Foster City, CA). The mRNA 
quantitation for each sample was normalized to 18s. The primers and probes were 
ordered from Applied Biosystems (Foster City, CA).   
     
Statistical analysis 
 All data were expressed as mean ± SE. Data were evaluated for statistical 
significance by one-way and two-way analysis of variance (diet × strain), and 
significantly different group means were then separated by the least significant 
difference test by using SPSS 12.0 (SPSS Inc. Chicago, IL).  
 
1.4 Results 
Dietary consumption and body weight gain 
    Dietary calcium had no effect on food intake of each strain of mice (Table 1); 
however, reduced body weight gain was observed in both Ay/ApcMin/+ and ApcMin/+ 
mice fed medium and high levels of calcium (Table 2) compared to the low 
calcium diet group. The high calcium dairy diet reduced weight gain by 64% and 
98% in Ay/ApcMin/+ and ApcMin/+, respectively.   
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Table 1:  Average food consumption (g/day) of  Ay/ApcMin/+ and ApcMin/+ micea 
 
Diet Ay/ApcMin/+mice ApcMin/+ mice 
low calcium    4.00±0.11 3.47±0.10 
medium calcium    3.90±0.10 3.03±0.12 
high calcium dairy    4.16±0.17 3.28±0.24 





Table 2: Body weight gain (g) (in 5-6 weeks) of Ay/ApcMin/+ and ApcMin/+ mice in 
different diet groupsa 
 
Diet Ay/ApcMin/+mice ApcMin/+ mice 
low calcium diet 13.38±1.51 2.64±0.85 
medium calcium diet   8.78±1.72 1.95±0.74 
high calcium dairy diet     4.89±1.76* 0.03±0.95 
                a Data expressed as mean ± SE.                  





Effects of different calcium diets on fat pad mass and skeletal muscles  
    The high calcium diets resulted in marked reduction in body fat in both strains 
of mice (p = 0.008 in Ay/ApcMin/+; p = 0.023 in ApcMin/+). Feeding the Ay/ApcMin/+ 
mice the high calcium dairy diet resulted in reductions in abdominal, perirenal 
and subcutaneous fat depots of 47%, 58% and 53%, respectively (p = 0.003, Fig.3, 
Table 3) compared to the low calcium diet. This decrease was also found in the 
ApcMin/+ mice, in which the high calcium dairy diet caused decreases in three fat 
mass of 68%, 82% and 71%, respectively (Table 3).  
    Diet had no effect on skeletal muscle (soleus and gastrocnemius) mass (Table 
3).   
 
Effects of different calcium diets on tumor number and size  
     The level of dietary calcium had no effect on tumor multiplicity in the 
Ay/ApcMin/+ mice (Table 4). A lack of effect was also observed in ApcMin/+ mice 
fed the low and medium levels of calcium. However, when ApcMin/+ mice were 
placed on a high calcium diet, their tumor number was significantly higher by 














Fig. 3 Representative photographs of gross change in mice fed low (left),  
medium (middle) and high (right) calcium diets. 
A: Ay/ApcMin/+ mice;    B: ApcMin/+ mice. 
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Table 3: Effects of different calcium diets on fat mass and skeletal muscles1 
 Ay/ApcMin/+ mice ApcMin/+ mice 












Abdominal 1.92±0.19 a 1.47±0.23 a 1.03±0.28 b 0.40±0.1* 0.32±0.07* 0.13±0.03** 
Perirenal 0.92±0.11 a 0.63±0.09 a 0.39±0.07 b 0.17±0.06 0.10±0.03 0.03±0.01 
Epididymal 0.16±0.02 0.16±0.04 0.14±0.04 0.65±0.01 0.76±0.01 0.053±0.01 
Subcutaneous 2.93±0.24 a 1.96±0.26 a 1.38±0.32 b 0.48±0.12* 0.38±0.09* 0.14±0.03** 
Total fat mass 5.86±0.51 a 4.18±0.58 a 2.87±0.6 b 1.09±0.28* 0.85±0.19* 0.36±0.06** 
Soleus 0.01±0.004 0.01±0.005 0.01±0.005 0.02±0.01 0.02±0.01 0.02±0.003 
Gastrocnemius 0.05±0.01 0.06±0.01 0.06±0.01 0.06±0.01 0.06±0.01 0.08±0.01 
1Data expressed as mean ± SE 
a,b  Values in each row with different superscript letters are significantly different by One-way ANOVA (p<0.05) 
* Value is significantly different from ** value by One-way ANOVA (p<0.05)  
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Table 4. Effects of different calcium diets on tumor in the colon and intestine of 
Ay/ApcMin/+ mice and ApcMin/+ mice 



















Total tumor number/group 
Colon       
< 1mm -a - - - - - 
1.01-2mm 1b 1 1 1 - 2 
2.01-3mm 1 1 1 - 1 3 
3.01-4mm - - 1 2 1 2 
>4mm - - - - 1 - 
Small intestine       
<0.5mm 17 13 9 8 5 4 
0.51-1mm 105 111 108 68 107 137 
1.01-1.50mm 70 109 104 84 125 258 
1.51-2mm 27 49 60 27 54 105 
2.01-2.5mm 6 15 14 15 12 21 
2.51-3mm 4 2 2 5 10 4 
>3mm - - - 1 2 1 
Total number/group 231 301 300 211 318 537 
Average 
tumor/mousec 
33.43±2.65 42.86±8.66 47.71±2.55 29.71±5.13d 42.57±6.90d 74.29±12.80e 
Average tumor size 1.21±0.45 1.31±0.48 1.33±0.35 1.32±0.55 1.41±0.88 1.42±0.48 
a None observed 
b number of tumors 
c Data expressed as mean ± SE 
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Correlation between body fat mass and tumor number 
    There were significant negative correlations between fat pad mass (sum of 
abdominal, subcutaneous, epididymal and perirenal fat) and tumor number in both 
mouse strains (r = -0.673 in Ay/ApcMin/+ mice, p<0.001; r = -0.450 in ApcMin/+ 
mice, p < 0.002) (Fig.4).  
 
Effects of calcium diets on plasma leptin and insulin levels  
    Plasma leptin levels in the Ay/ApcMin/+ mice were progressively lower in the 
medium and high calcium groups compared to the low calcium group (28.2 ± 
9.1ng/ml and 19.0 ± 2.0ng/ml versus 51.4 ± 7.6ng/ml, respectively), but diet had 
no effect on serum leptin levels in the ApcMin/+ mice (Fig.5). Two-way ANOVA 
analysis showed that the overall plasma leptin levels were higher in the 
Ay/ApcMin/+ mice as compared to ApcMin/+ mice with all levels of dietary calcium 
(p < 0.01).  
   Dietary calcium exerted no effect on plasma insulin levels in either Ay/ApcMin/+ 
or ApcMin/+ mice (Fig.6); however, the overall insulin levels of ApcMin/+ mice were 







Fig.4 Correlation between body fat mass and tumors 












Fig.5 Effects of calcium diets on plasma leptin levels of Ay/ApcMin/+ (□) mice 
and ApcMin/+ mice (■). 
*  p < 0.02 vs. low calcium diet group  in Ay/ApcMin/+mice; 










Fig.6 Effects of calcium diets on plasma insulin levels of 











Effects of calcium diets on intestinal tumor β-catenin and cyclin D1 gene 
expression 
    In Ay/ApcMin/+ mice, intestinal tumor there were no significant differences in β-
catenin levels between the high and low calcium diets. 
    In contrast, ApcMin/+ mice on the high calcium diet had tumors with 142% 
higher levels of β-catenin gene expression (Fig. 8D, p < 0.05) in comparison with 
the low calcium diet.              
  *
    △
     In addition cyclin D1 mRNA, a transcriptional target of β-catenin, was also 
significantly higher in the mice fed the high calcium dairy diet compared to those 














Fig.7 Effects of calcium diets on Ay/ApcMin/+ mice intestinal tumor tissue 










Fig.8 Effects of calcium diets on ApcMin/+ mice intestinal tumor tissue gene 
expression. 
A: Bax; B: Bcl-2; C: Bcl-2/Bax ratio; D: β-catenin 









Fig.9 Effects of calcium diets on ApcMin/+ mice intestinal tumor 
cyclin D1 gene expression. 






    Colorectal cancer is the third most commonly diagnosed type of tumor in the 
United States and the second or third most common cause of cancer-related 
mortality (21). Its prevalence is higher in Western societies and environmental 
factors, in particular diet, is believed to have a significant impact on this disease 
process. Epidemiological studies suggest an inverse relationship exists between 
dietary calcium and colorectal cancer risk (22). Calcium may help to directly 
inhibit colonic epithelial proliferation by precipitating bile acids and fatty acids 
and thereby reduce the cellular toxicity within the colonic lumen (23). 
Extracellular calcium may also act in the regulation of cell proliferation and 
differentiation by sensing CaSR (calcium sensing receptors), followed by a 
cascade of diverse intracellular signaling pathways (24). The inverse effect 
between dietary calcium and colon cancer risk has also been linked 
mechanistically to indirect effects on vitamin D metabolism (i.e., changes in 
circulating calcitriol and 25-(OH)-D3), effects as a first messenger (i.e., via 
calcium-sensing receptor) and as a second messenger (changes in the intracellular 
calcium concentrations), with subsequent downstream effects on pathways 
influencing the balance between proliferation and apoptosis (25). However, 
studies evaluating the effects of dietary calcium on tumorigenesis using 
experimental rodent models have been equivocal and this paper explores a novel 
mechanism which appears to potentially contribute to this variability. 
    In contrast to data describing an inverse relationship between dietary calcium 
and colon cancer risk, recent data from the Women’s Health Initiative 
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demonstrate no effect of moderately long-term (7 year) calcium supplementation 
on the incidence of colorectal cancer among post-menopausal women (26).  This 
negative finding may be attributable, in part, to the long latency associated with 
colorectal cancer.  However, in light of findings from the present study, it is also 
possible that putative protective effects of calcium against colorectal cancer may 
be least apparent among lean individuals, suggesting that future studies of calcium 
and colorectal cancer should consider stratification of subjects according to 
adiposity. 
    A diet based on AIN-93G (Research Diets, Inc. NJ), a dietary formula for 
gestating and growing rodents as recommended by the American Society for 
Nutrition (27) was modified with three levels of dietary calcium. The typical 
AIN-93G diet contains 0.5% calcium by weight, or 1.2mg/kcal. If one assumes an 
equivalency between recommended levels in laboratory animals and humans, the 
0.5% calcium diet used in this experiment would be equivalent to a human intake 
of 1,000 mg, while the low (0.2%) and high (1.2%) calcium diets would be 
equivalent to 400 mg and 2,400 mg for humans, respectively. These equivalencies 
cannot be calculated with certainty, as establishing human equivalency with 
experimental rodent diets is problematic; several approaches have been suggested, 
including body weight, body surface area, metabolic rate and energy density (28).  
However, none of these produce a satisfactory equivalency for calcium. For 
example, using the energy density approach demonstrates that the 0.5% level of 
calcium used in The AIN-93 diet (27) and recommended by the National 
Research Council (US) (29) contains 1.2 mg Ca/kcal, which extrapolates to a 
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human dietary calcium intake of 3,000 mg/day for an individual consuming 2,500 
kcal/day, a level in excess of the Upper Limit for safety established by the Food 
and Nutrition Board of the National Academy of Sciences (US). This 
extrapolation is clearly not tenable, as this level of calcium intake (0.5%) is not 
toxic to rats or mice and is instead consistent with a level that supports optimal 
performance (29). Moreover, Chandler and Cragle (30) demonstrated that optimal 
growth and skeletal mineralization performance of the growing laboratory rat 
occurred between 0.5 and 0.67% calcium, consistent with the aforementioned 
recommendations (27, 29). Consequently, in the absence of any ideal method of 
calculating mouse-human equivalency, in the present study we have evaluated 
departures from the recommended levels for the mice, bracketing the 
recommended level with a lower level (0.2%, or 40% of recommended levels) and 
a higher level (1.2%, or 2.4-fold higher than recommended and 3-fold higher than 
the lowest level used in this study).   
     This study demonstrated that a high calcium diet surprisingly resulted in a pro-
tumorigenic effect which may not be related to previously reported mechanisms 
of calcium, but rather indirectly associated with its anti-obesity effects. The 
amount of calcium and the vehicle of the supplementation appear to be critical for 
this response, particularly in ApcMin/+ mice, an accepted model of intestinal 
tumorigenesis which has been shown to be sensitive to dietary intervention (31-
34).  Previously, it had been demonstrated that providing ApcMin/+ mice variable 
levels of elemental calcium in the form of calcium carbonate (0.2% - 1.2%, w/w) 
had no effect on tumor load (34), and these results have been recapitulated in our 
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laboratory (unpublished data). Data from human studies indicate that elemental 
calcium and dairy calcium have responded equivalently (35). However, we 
previously found that when calcium was provided in the form of non-fat dry milk, 
tumor number was 52% higher in animals provided a high dose of calcium (1.2%, 
w/w) versus a low dose of calcium (0.2%, w/w calcium carbonate) (an average of 
62 tumors/mouse versus 41 tumors/mouse, respectively, from replicate studies) 
(unpublished data). This increase in tumorigenesis is in apparent opposition to the 
effect of dairy calcium on colon cancer biomarkers (36).  It is possible that this 
effect is unique for dairy calcium and/or dairy products containing calcium; 
however, this is highly unlikely since dairy contains significant levels of other 
bioactive components that have been shown to decrease the number of tumors in 
animal models, such as vitamin D (37), butyrate (38) and sphingomyelin (39). 
Increasing circulating levels of 25-(OH)-D3 have been shown to have an inverse 
relationship on cancer risk (40) and reduce epithelial cell proliferation (41). 
Calcium supplementation has been shown to decrease 25-(OH)-D3 levels in 
ApcMin/+ mice (35). However, tumor number in ApcMin/+ mice were unaffected by 
treatment with the active form of vitamin D (1, 25-(OH)2-D3) or a non-calcemic 
active synthetic analogue (42).  In addition, while differences were modest and 
not statistically significant, tumor loads were higher in the mid-range than low 
level calcium (carbonate) diets and fat deposits were decreased. 
    One consistent aspect associated with all of our studies was the virtual absence 
of adipose tissue in the ApcMin/+ mice fed high levels of dairy calcium. ApcMin/+ 
mice tend to have smaller fat pad mass compared to genetically matched 
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C57BL/6J controls when fed ad libitum, but nevertheless, adipose tissue is always 
visibly present. However, placing the animals on a high dairy calcium diet 
resulted in additional loss of residual adipose tissue. These results are consistent 
with the anti-obesity effect of dietary calcium (14, 43-45); an effect which is 
substantially more prominent with dairy calcium than it is with elemental calcium 
(44). Thus, it is possible that the neoplastic effects of dairy calcium under these 
experimental conditions are related to the profound loss of fat mass. 
    To address this question and confirm our results, we wanted to either eliminate 
adipose tissue via an alternative method while maintaining caloric intake (thus 
mimicking our experimental conditions), or enhance the levels of fat in ApcMin/+ 
mice such that a sufficient amount of residual adipose tissue would be present 
after placing the mice on a high dairy calcium diet.  With regards to the first point, 
it has already been established that reducing caloric intake by 40% reduces tumor 
number by >50% in this model (46), and there is no other dietary mechanism 
known to achieve similar effects on reducing adiposity outside of adding dairy 
calcium. Regarding the second point, we couldn’t sufficiently “fatten up” the 
mice prior to placing them on a high dairy calcium diet because they have a 
relatively short life span (<120-140 days) and it was observed that these mice do 
not consume enough food (typically 2.5-3 g/d) (34) to generate excess adipose 
tissue necessary for this type of an experiment. 
    Therefore, to adequately address this problem, we crossed the “tumor-prone” 
ApcMin/+ mouse with the “obesity-prone” Ay/a mouse to generate a “fat” 
Ay/ApcMin/+mouse cross. For this experiment to be successful, the cross would 
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have to have the same genetic background to eliminate the introduction of tumor 
modifying loci, have no impact on tumorigenesis, and yet have larger fat pad 
mass compared to ApcMin/+ mice.  All of these conditions were met with the cross: 
the backgrounds of the mice were genetically matched (C57BL/6J strains), the 
cross did not modify tumor load (preliminary data not presented), and the amount 
of adiposity was significantly higher in the Ay/ApcMin/+mice versus the ApcMin/+ 
mice. Recapitulating our earlier results, tumor number was significantly higher in 
the ApcMin/+ mice fed the high dairy calcium diet (1.2%) compared to the mice fed 
standard (0.5%) or insufficient amounts of calcium (0.2%). These mice were 
almost devoid of any visible adipose tissue. However, tumor load was not 
significantly different in Ay/ApcMin/+mice fed the high dairy calcium diet despite 
the same dose response (inverse relationship) between dietary calcium and level 
of adipose tissue. 
    These data suggest that a minimum amount or threshold level of adipose tissue 
may be required to significantly attenuate the augmented tumorigenic response 
observed in the ApcMin/+ mice on the high calcium diets. If this were the case, the 
differential effect of dairy calcium on intestinal tumorigenesis may result from the 
loss of adipose-derived signaling molecules (i.e., adipokines) due to the 
substantial loss of body fat. It is possible that one or more of these adipokines 
(i.e., leptin, resistin, adiponectin, TNF-α, etc.) could directly or indirectly 
suppress tumorigenesis. In support of this concept, there were significant negative 
correlations between body fat mass and tumor number in both strains of mice, 
suggesting that intestinal tumor load could be predicted, in part, by the level of 
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body fat. There is, in fact, precedent for this concept. Cachexia is defined as a 
syndrome of progressive wasting characterized by significant loss of adipose 
tissue and lean body mass (47). Patients with malignancy-related cachexia 
experience prolonged survival with nutritional intervention, and this improved 
outcome is significantly correlated with increased body fat (48). Body fat is lost 
more rapidly than skeletal muscle in cancer patients suffering from cachexia, and 
the level of whole body fat significantly predicts survival, whereas lean tissue 
does not (49).  
    Data from the present study cannot be interpreted to suggest that excess adipose 
tissue mass is protective against colorectal cancer, as there is a well established 
positive relationship between obesity and colorectal cancer.  Instead, these data 
suggest that excessive loss of adipose tissue results in loss of critical adipocyte-
derived protective factors, although these factors have not yet been definitively 
identified. 
    The Ay/ApcMin/+mice were significantly heavier with larger fat pad mass than 
their ApcMin/+ counterparts, and this difference was reflected in higher circulating 
levels of leptin, a biomarker of adipose tissue (Fig. 3). We also observed that 
insulin levels in ApcMin/+ mice were higher than that of Ay/ApcMin/+mice, which 
suggests moderate insulin resistance in these animals. Although insulin is a 
growth factor, this effect does not explain the increase tumor number in ApcMin/+ 
on the high dairy calcium diet. 
    β-catenin expression was enhanced in ApcMin/+ mice on the high dairy calcium 
diet. Elevated level of β-catenin in the cytoplasm and nucleus is an important 
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characteristic and driving force of colorectal cancers; modifying aberrant β-
catenin expression can influence tumorigenesis (50). One of the transcriptional 
targets of nuclear β-catenin is cyclin D1, which directly contributes to cell 
proliferation in these neoplastic cells. Cyclin D1 protein inactivates the 
retinoblastoma protein and promotes progression through the G1-S phase of the 
cell cycle (51). Consequently, higher cyclin D1 gene expression in the tumors of 
ApcMin/+ mice on a high calcium dairy diet (Fig. 7) is consistent with increased 
tumor growth as well as higher levels of β-catenin, when compared to the low 
calcium fed group.  
     In summary, when ApcMin/+ mice were fed a diet high in dairy calcium, their 
tumor frequency increased by 74% and 150% as compared to mice fed standard 
and suboptimal levels of calcium, respectively. Concomitantly, these animals 
experienced substantial loss of adipose tissue and, when a modicum of adipose 
tissue was retained in animals fed the high calcium diary diet, as a result of cross-
breeding of “tumor-prone” ApcMin/+ mouse with  “obesity-prone” Ay/a mouse to 
generate a “fat” Ay/ApcMin/+mouse, this enhanced tumorigenesis was abrogated. 
These data suggest that excessive loss of marginal adipose tissue stores may 
promote tumorigenesis, and the differential effect of dietary calcium on intestinal 
tumorigenesis may result at least in part, from the loss of adipose-derived 
protective factor(s) due to the absence of body fat. Studies are currently underway 
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2. The Anti-proliferative Effect of Adiponectin on Human Caco-2 


























    Our previous work with ApcMin/+ (Min) mice suggests that loss of critical 
protective factor(s) from excessive loss of body fat on a high calcium diet results 
in increased intestinal tumor susceptibility. Given that obesity is a risk factor for 
colon cancer and that plasma adiponectin level is inversely associated with the 
incidence of obesity, we hypothesized that adiponectin may have anti-
proliferative effect on Caco-2 cell proliferation, and that excessive loss of body 
fat in the already lean Min mice would lead to loss of this effect. Consequently, 
we have now examined the effect of human adipocytes and pre-adipocytes on 
growth of Caco-2 cells and the role of adiponectin in mediating this effect. 
Human adipocyte conditioned medium (HACM) inhibited Caco-2 cell growth by 
28.0%-65.6% (p < 0.03) compared with DMEM, while human pre-adipocyte 
conditioned medium (HPCM) exerted no effect. Co-culturing Caco-2 cells with 
human adipocytes substantially suppressed Caco-2 proliferation by 62.8% 
(+10.1%, p = 0.013). Addition of a neutralizing anti-adiponectin antibody to the 
HACM and to the co-culture system completely reversed the inhibitory effects of 
human adipocytes on Caco-2 proliferation, indicating that adiponectin is 
responsible for this inhibitory effect.  Similarly, a siRNA-mediated decrease in 
adiponectin protein in human adipocytes prevented the inhibitory effect of human 
adipocytes on Caco-2 proliferation. These data demonstrate that human 
adipocytes inhibit Caco-2 proliferation and that adiponectin is responsible for this 
effect. These results highlight the importance of stromal-cancer cell interactions 
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and suggest that adiponectin secreted by mature adipocytes may be a key 

























Obesity is consistently associated with increased risk of colorectal cancer in 
men and women in both case-control and cohort studies (1). Among the biological 
mechanisms linking body size to colorectal cancer, mounting evidence suggests 
that adipokines such as leptin, adiponectin, and tumor necrosis factor-α (TNF-α), 
which are produced by adipocytes and function to regulate adipocyte homeostasis 
and metabolism, are associated with colorectal neoplasia (2).  
Adiponectin is a cytokine secreted from white adipose tissue. Adiponectin acts 
as an insulin-sensitizing hormone (3, 4) but also has anti-inflammatory (5) and 
anti-atherogenic effects (6, 7). Unlike leptin and TNF-α, circulating adiponectin 
levels are decreased with increasing adiposity (8, 9). Low levels of adiponectin 
may thus provide a link between obesity and risk of colorectal cancer. This 
hypothesis has been evaluated in several epidemiological studies. Otake et al. 
performed a case-control study to examine visceral fat accumulation and the 
levels of adiponectin in Japanese patients with colorectal adenoma. They reported 
that the patients with colorectal adenoma showed significantly more visceral fat 
and significantly less plasma adiponectin concentration in comparison with the 
controls (adds ratio (OR)=2.19, 95% confidence interval (95% CI)=1.47-3.28; p < 
0.001 and OR=0.24, 95% CI=0.14-0.41; p < 0.001, respectively) (10). Wei and 
coworkers conducted another study to evaluate the association between plasma 
adiponectin and risk of colorectal cancer among 18,225 men in the Health 
Professional Follow-up Study. In this ongoing prospective cohort study, they 
observed a statistically significant inverse association between plasma levels and 
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risk of colon cancer (11). However, one observational case-control study 
contradicts the epidemiological data linking adiponectin to colon carcinogenesis 
(12). In that study, serum adiponectin levels were determined from 381 colorectal 
cancer cases and 381 controls. The results showed that there was no association 
between adiponectin level and risk of colorectal, colon, or rectal cancer in the 
whole study population.  
Our previous work with the ApcMin/+ mice suggests that loss of critical 
protective factor(s) from excessive loss of body fat on a high calcium diet results 
in increased intestinal tumor susceptibility (13), which is supported by the study 
of Abramowits et al (14). Since plasma adiponectin is inversely associated with 
adiposity, it is possible that circulating levels of adiponectin partially explain the 
observed association between increased cancer susceptibility and either high or 
excessively low body fat mass. Therefore, we hypothesized that adiponectin may 
has anti-proliferative effects on colon cancer cell proliferation, and that excessive 
loss of body fat in the already lean Min mice would lead to loss of this effect. 
Consequently, we utilized an in vitro co-culture system and siRNA to examine the 
influence of human adipocytes on the growth of Caco-2 cells. We report here that 
the presence of adipocytes substantially suppressed Caco-2 proliferation, while a 
siRNA-mediated decrease in adiponectin protein in human adipocytes prevented 
the inhibitory effect of human adipocytes on Caco-2 proliferation. These data 
indicate that adiponectin may suppress colorectal tumorigenesis and that loss of 
this effect in lipodystrophic min mice may be responsible for observed increases 
in tumor load. 
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2.3 Materials and Methods 
 
Reagents   
    Dulbecco’s modified essential medium (DMEM), penicillin-streptomycin, 
Opti-MEM I reduced serum medium, Hanks’ Balanced Salt Solution (HBSS) and 
0.05% trypsin-EDTA were purchased from Invitrogen (Carlsbad, CA). Fetal 
bovine serum (FBS) and Eagle’s minimum essential medium (MEM) were 
purchased from American Type Culture Collection (ATCC) (Manassas, VA). 
Adiponectin antibody was purchased from Sigma Chemical Co. (St. Lous, MO). 
Cell proliferation Biotrak ELISA system was obtained from GE Healthcare 
(Piscataway, NJ). Human adiponectin ELISA Kit was purchased from Linco 
Research (St. Charles, MO). CyQuant cell proliferation Kit was obtained from 
Invitrogen (Carlsbad, CA). 
 
Cell culture  
     Human preadipocytes were maintained in preadipocyte medium. 12-well plate 
human adipocytes were purchased from Zen-Bio, Inc. (Research Triangle Park, 
NC) and cultured in adipocytes medium. Caco-2 cells were obtained from ATCC 
and maintained in MEM containing 2mM L-glutamine, 1.5 g/L sodium 
bicarbonate, 0.1mM non-essential amino acids, 50 IU/ml penicillin, 50 μg/ml 
streptomycin and 10% FBS. 
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Preparation of human adipocyte conditioned medium (HACM) and human 
pre-adipocyte conditioned medium (HPCM)  
    Human adipocytes and pre-adipocytes were maintained in adipocyte medium or 
pre-adipocyte medium for 24 h, respectively and conditioned medium was then 
prepared by incubation of the cells in serum-free medium (0.2% FBS containing 
DMEM) for 3 days. Control medium was prepared according to this procedure 
but without cells. The collected conditioned media were centrifuged at 800×g for 
5 min to remove cellular components and used in fresh.  
 
Cell proliferation experiments  
    Caco-2 cells were plated at a density of 1 x 104  cells/ml in 96-well plates and 
incubated at 37°C in DMEM plus 10% FBS. After 24 h the cultures were washed 
and refed with fresh HACM or HPCM. Control cells were cultured in serum-free 
DMEM. At 24, 48, 72, and 96 h the cells were washed with HBSS and cell 
proliferation was examined by immunohistochemistry for bromodeoxyuridine 
(BrdU) using the cell proliferation ELISA kit.  
 
Transwell co-culture experiments  
    Human adipocytes or human preadipocytes were co-cultured with Caco-2 cells 
in the Transwell system separated by a polyester permeable support (Corning-
Costar, Cambridge, MA). To examine the effect of adipocytes and preadipocytes 
on Caco-2 growth, Caco-2 cells were seeded on 12-well Transwell inserts (0.4 μm 
pore size). After 24 h culture in DMEM/10% FBS, cells were washed with HBSS 
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and the Transwells containing Caco-2 cells were transferred to 12-well plates with 
human adipocytes or preadipocytes previously maintained in serum-free DMEM 
for 24 h. Control cells were also grown on the Transwell inserts but in the absence 
of underlying cells. Media were changed every 2 days. Following the co-culture 
for 1, 2, 3 or 4 days, Caco-2 cells in the inserts were detached by 0.05% trypsin-
EDTA and counted by hemocytometer. DNA content measurement was 
determined by using CyQuant Kit.  
 
Human adiponectin neutralizing antibody treatment studies  
    Anti-adiponectin was added into the 3-days collected HACM or co-culture 
system at 150ng/ml before the experiment. The HACM treatment and co-culture 
experiment were then performed as described.  
 
ELISA for human adiponectin   
    Human adiponectin was determined by using ELISA kit according to the 
manufacturer’s protocol (Linco Research INC. St. Charles, MI).  
 
siRNA   
    All siRNA materials were from Ambion (Austin, TX). KDalertTM GAPDH 
assay kit and GAPDH mRNA expression through qRT-PCR were used to monitor 
siRNA transfection in human adipocytes and to optimize the transfection 
protocol. Negative siRNA refers to SilencerTM Negative Control#1 siRNA. 
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Adiponectin siRNA refers to pre-designed siRNA ID 148359. siRNA stock 
solution was prepared in 20μM in RNase-free water.  
 
RNA interference and transfection  
    siRNA transfection was performed on human adipocytes following maintaining 
in adipocyte medium for 24 h. Adipocytes were washed with Opti-MEM I 
reduced serum medium and maintained in 400 μl per well prior to siRNA 
trasnsfection. Cells were transfected with 2 μl adiponectin siRNA or negative 
control using 3 μl per well siPORT TM Lipid Transfection Agent according to the 
manufacturer’s protocol. Four hours after addition of the siRNA/transfection 
agent complex, 3 ml adipocyte medium was added to each well. Twenty-four 
hours after transfection, adipocytes were washed with Opti-MEM I reduced serum 
medium and the transfection was repeated. Forty-eight hours after the second 
transfection, cell culture medium was replaced with serum-free medium. Then, 
the adipocytes were cultured for 24 h before the start of co-culture experiment. 
During the transfection and co-culturing, the down-regulation of the adiponectin 
targeted by siRNA was confirmed by analysis of its expression level using human 
adiponectin ELISA and quantitative RT-PCR.  
 
Total RNA extraction and quantitative real-time PCR 
Total RNA was extracted from human adipocytes transfected with adiponectin 
siRNA or negative controls by using total cellular RNA isolation Kit from 
Ambion (Austin, TX) according to the manufacture’s instruction. RNA 
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concentration and quality were determined using Nanodrop ND-1000 
Spectrophotometer (Nanodrop technologies, Wilminton, DE). RNA samples were 
stored at −80°C. Human adiponectin gene expression level was measured 
quantitatively using 7300 Real Time PCR system with One-step RT-PCR Master 
Mix (Applied Biosystems, Foster City, CA). The mRNA quantitation for each 
sample was further normalized by GAPDH. The primers and probes were 




     All data were evaluated for normality of distribution and equality of variance 
prior to statistical analysis. Outcomes were shown as means ± SD and were 
evaluated for statistical significance by one-way analysis of variance (ANOVA) 
and t test to compare group means using SPSS 14.0 (SPSS Inc, Chicago, IL). 
 
2.4 Results 
HACM inhibits Caco-2 cell proliferation  
 
Conditioned medium from human adipocytes inhibited Caco-2 cell 
proliferation. 25% HACM significantly inhibited Caco-2 cell proliferation at day 














Fig. 10 Effects of HACM on Caco-2 cell proliferation 

















HPCM has no effect on Caco-2 cell proliferation 
    Compared with the DMEM treatment group, 3-days collected conditioned 
medium from human pre-adipocytes exhibited no effect on Caco-2 cell 
proliferation (Fig. 11). 
 
Effects of human adipocyte and Caco-2 co-culture 
 
Co-culturing human adipocytes and Caco-2 cells decreased Caco-2 cell 
proliferation, especially in day3 (p < 0.05, Fig. 12). Cell number was decreased by 
62.8%±10.1% (p = 0.013, Fig. 12A) compared to the control group, and DNA 
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Fig. 12 Effects of co-culturing with human adipocytes on Caco-2 cell 
proliferation 
A: cell number was counted by hemocytometer 
B: DNA content was determined by CyQuant cell proliferation Kit. 





Effects of human pre-adipocyte and Caco-2 cell co-culture 
 
    In contrast to the effects of adipocytes, co-culturing human pre-adipocytes and 




Effect of Anti-adiponectin 
When the anti-human adiponectin-neutralizing antibody was added into the 
HACM, the growth-inhibiting effect of HACM was abolished (Fig. 14A), and 
there was an increase in Caco-2 cell proliferation on day2 (Fig. 14A). Similar 
results were found in the co-culture system (Fig. 14B). 
 
Effects of adiponectin siRNA transfection of human adipocytes  
    Human adipocytes were transfected with Pre-Designed siRNA-adiponectin 
using siPORTTM Lipid Transfection Agent as carrier. Highest transfection 
efficacy (70%) was obtained using the siRNA at a concentration of 80 nM in 
0.6% (v/v) siPORTTM Lipid Transfection Agent without any detectable effects on 
cell proliferation or differentiation (data not shown).  
 
 
RNA interference experiment  
 
    After transfection with adiponectin siRNA or negative control siRNA, human 
adipocytes were co-cultured with Caco-2 cells for 4 days. As shown in Fig. 15, 
Silencing adiponectin reversed the inhibitory effect of adipocytes on Caco-2 cell 










Fig. 13 Effects of co-culturing with human pre-adipocytes on Caco-2 cell 
proliferation 
A: cell number was counted by hemocytometer 














Fig. 14A  Effects of anti-adiponectin treatment on HACM inhibition of 
Caco-2 cell proliferation 






















Fig.14B Effects of anti-adiponectin treatment on adipocyte co-culture inhibition 
of Caco-2 cell proliferation B-1: cell number was counted by hemocytometer 
B-2: DNA content was determined by CyQuant cell proliferation Kit. 













Fig. 15  Effect of adiponectin siRNA on Caco-2 cell proliferation during co-
culture with human adipocytes 
* Value is significantly different from ** value by One-way ANOVA (p<0.05) 






      
    Data from this study demonstrate that the anti-proliferative signal derived from 
human adipocytes appears to be mediated by adiponectin. Adipocytes, a 
predominant stromal cell type, can secret adipokines and growths factors and 
thereby significantly regulate growth of epithelial cells. To date, several growth-
promoting adipokines have been well characterized. For example, leptin is a small 
adipocyte-derived hormone, and Hardwick et al. demonstrated that leptin had 
mitogenic properties and can stimulate growth of colon cancer cells (15). 
Furthermore, a Norwegian study found a positive association between incident 
colorectal cancer risk and serum levels of leptin (16). TNF-α, a candidate gene for 
obesity and insulin resistance, is a pro-inflammatory molecule. It may be involved 
in the pathway linking obesity to colorectal cancer. Hepatocyte growth factor 
(HGF), synthesized and secreted from mature adipocytes, also shows the ability 
of promoting in vitro growth of breast cancer cells (17). In this study, we have 
shown for the first time that adipocyte conditioned medium, but not pre-adipocyte 
conditioned medium, inhibits Caco-2 cell proliferation. Adipocytes are believed 
to stem from fibroblast-like stem cells (preadipocytes) present in the stromal-
vascular fraction (18, 19) of adipose tissue. Therefore, it is possible to observe the 
specific effect of adipocytes on Caco-2 by using preadipocytes as a control. 
Interestingly, our data show that the growth-inhibiting effect of mature adipocytes 
is not dose-dependent. HACM in lower concentration (25%) suppressed Caco-2 
cell proliferation much stronger than the higher concentration (50%). Since both 
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pro-proliferative factors and anti-proliferative factors exist in HACM, these data 
suggest a complex interaction among these factors.  
    Unlike human adipocytes and HACM, human pre-adipocytes and HPCM did 
not show an inhibitory effect on Caco-2 cells proliferation. This difference must 
clearly be due to factor(s) that are derived from mature adipocytes, but not pre-
adipocytes; adiponectin is well established as one such factor (20).   
    Accumulating epidemiological evidence links adiponectin inversely to risk of 
cancers of the endometrium (21-23), breast (24, 25) and colon (10, 11), and recent 
laboratory studies support an anti-tumor activity of adiponectin. Brakenhielm et 
al. reported a unique function of adiponectin as a negative regulator of 
angiogenesis, which is critical for tumor growth (26). Adiponectin has also been 
shown to drastically suppress the growth of mylomonocyte leukaemia cell lines 
and to induce apoptosis in these cell lines (5). Moreover, there have been two 
recent studies report that adiponectin is capable of suppressing cell growth in 
MDA-MB-231 (27, 28) and in MCF-77 (29) breast cancer cell line. However, the 
mechanisms that underlie adiponectin and colon carcinogenesis have not been 
clarified. In our pilot experiment, we found that treatment of Caco-2 cells with 5 
μg/ml human recombinant adiponectin, mimicking the human plasma adiponectin 
level (9), suppressed Caco-2 cell proliferation. Thus, we hypothesized that 
adiponectin might be responsible for the growth-inhibiting effect of HACM.  
    To further determine whether adiponectin contributes to this inhibitory effect, 
neutralizing antibody against adiponectin was used. We selected the level of 
antibody (150 ng/ml) based on the level of adiponectin in HACM, and the data 
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showed that anti-adiponectin almost completely abrogated the growth-inhibitory 
activity of HACM.  
    The co-culture system is a model that focuses on stromal-cancer interactions. 
Although in vivo studies illustrate that characterize human epithelial cells require 
the presence of human adipose tissue, most in vitro studies used either 3T3-L1 
CM (17, 30) or 3T3-L1 adipocytes (31), or mammary mature adipocytes (32). To 
our knowledge, our experiments are the first to utilize viable mature human 
adipocytes in co-culture with colon cancer cells. In the current study, we used a 
transwell insert system to physically separate the human adipocytes and Caco-2 
cells, while still allowing the free exchange of low molecular weight factors. In 
agreement with previous experiments, we found that adipocytes inhibited Caco-2 
cell proliferation and that neutralizing adiponectin with an antibody reversed this 
effect.  
    RNA interference is now an established technology that is widely used for 
highly specific gene silencing in various cell types (33). Previous studies 
identified conditions for siRNA-based gene silencing in cultured 3T3-L1 
adipocytes (34-36), but had not yet been generally applied to human adipocytes. 
In the present study, we first optimized the siRNA conditions for human 
adipocytes to knock down adiponectin gene expression for 5 days. We achieved a 
70% knock down of adiponectin and the efficiency was maintained throughout 
the experiment, as demonstrated by measuring adiponectin levels from day 1 to 
day 4. When introduced in the co-culture system, silencing adiponectin not only 
reversed the growth-inhibiting effect of human adipocytes on Caco-2 
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proliferation, but also increased Caco-2 cell growth, similar to the anti-
adiponectin results. These results indicate that adiponectin contributes to the 
regulation of Caco-2 cell proliferation, and adiponectin knockdown-human 
adipocytes stimulated Caco-2 proliferation.  
    In summary, we have demonstrated human adipocytes, but not pre-adipocytes, 
inhibit Caco-2 cell proliferation. This inhibitory effect appears to be due to 
adiponectin secreted by mature adipocytes. Our results have led to a new insight 
into the role of adiposity in colorectal tumorigenesis. Further work will be 
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The strong association between high calcium intake and lower colorectal cancer 
risk, and between obesity and higher colorectal cancer risk have been generally 
accepted. However, studies presented here support the hypothesis that increased 
intestinal tumorigenesis in ApcMin/+ mice on high calcium diets is due to the 
extreme loss of body fat, therefore providing a new perspective on the role of 
adipose tissue; that is, a minimum amount or threshold level of adipose tissue may 
be required to significantly attenuate the augmented tumorigenic response 
observed in the ApcMin/+ mice on a high calcium diet. Our studies also suggested 
that tumor load was not significantly different in Ay/ApcMin/+mice fed the low, 
normal and high calcium diets despite the significant inverse relationship between 
dietary calcium and level of adipose tissue was observed, further suggesting that 
adequate level of body fat may protect against excessive intestinal tumor load.       
Adipokines are likely candidates to explain the role of adipose tissue in the 
incidence of colorectal cancer. Data from present study demonstrate that human 
adipocytes have the ability to inhibit human Caco-2 cell proliferation via an 
adiponectin-dependent mechanismcan. Accordingly, loss of this effect in 
lipodystrophic min mice fed high calcium diet may be responsible for observed 
increases in tumor load. 
In conclusion, we demonstrate that the increased intestinal tumor susceptibility 
is partially due to the loss of adiponectin from excessive loss of body fat in min 
mice on high calcium diets. Futher studies of the precise role of adiponectin in 
regulating tumorigenesis should be conducted in both in vivo and in vitro 
 165
experimental models. We hypothesize that the protective effect of adiponectin 
could be achieved by reducing cell proliferation, improving insulin resistance and 
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